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Abstract 
 
The objectives of this thesis were to clarify the distributions of lymph nodes (LNs) 
and lymph vessels (LVs), the communication between lymphatics and the surrounding 
veins, and the relationship between cancer metastasis and the lymphatic system in 
MXH10/Mo/lpr, a lympho-proliferative in-bred mouse, to extrapolate the findings to 
develop potential new clinical treatments.  
In Chapter 1, overviews of cancer metastasis, the lymphatic system and the 
relationship between them are outlined. An extensive literature review strongly 
indicated that the lymphatic system facilitates cancer cell dissemination throughout the 
body, acting in concert with the venous system. It is clear that preclinical models of LN 
metastasis are indispensable to aid the understanding of the mechanisms involved in 
tumor cell trafficking, which are fundamental for developing new techniques to 
diagnose and treat LN metastasis. 
However, the identification of LNs and LVs in mice is challenging with 
conventional imaging modalities, since the LN diameter in normal mice is 1–2 mm. In 
this thesis, a preclinical model of LN metastasis has been used involving 
MXH10/Mo-lpr/lpr (MXH10/Mo/lpr) inbred mice, which develop systemic swelling of 
LNs up to 10 mm in diameter. 
In Chapter 2, the aim was to identify LNs and LVs in MXH10/Mo/lpr mice and 
establish one of the peripheral inter-LN routes that can induce regional lymphatic cancer 
metastasis. Twenty-two different LNs were found distributed in the peripheral, thoracic 
and abdominal regions, and 4 peripheral inter-LN vessels were identified, from the 
subiliac LN (SiLN) to the proper axillary LN (PALN), the parotid LN to the caudal deep 
cervical LN, and the popliteal LN to both the sciatic LN and the SiLN. Moreover, 
peripheral regional metastasis was induced by inoculating FM3A/Luc mouse breast 
cancer cells into the SiLN. This chapter unveils the anatomy of murine lymphatics to 
give new insights into the investigation of inter-LN metastasis of cancer, especially the 
mechanisms involved in the trafficking of cancer cells in inter-LN vessels. The 
lymphatic anatomy data will be useful in the quest for deepening our understanding of 
cancer cell trafficking and the mechanisms involved in cancer metastasis. The results 
 x 
 
also show, for the first time, that the MXH10/Mo/lpr mouse strain is an 
'investigator-friendly' and reliable model of peripheral inter-LN cancer metastasis. 
In Chapter 3, the communication pathways between the lymphatic and venous 
systems are clarified, with a focus on the anatomy of these communication routes in the 
axillary and subiliac regions. The communication pathways between the lymphatic and 
venous systems in the axillary and subiliac regions of mice were unequivocally 
identified. The efferent LVs of the PALN were demonstrated to communicate with the 
subclavian vein. Furthermore, it was shown that the thoracoepigastric vein (TV), which 
connects the subclavian vein and inferior vena cava, runs adjacent to the SiLN and 
PALN, and receives venous blood from these LNs routed through small branches. The 
direction of blood flow in the TV occurred in two directions in the intermediate region 
between the PALN and SiLN; one to the subclavian vein, the other to the inferior vena 
cava. This research reveals the anatomy of the communication between the lymphatic 
and venous systems in the axillary and subiliac regions of the mouse, and provides 
further lymphatic-venous anatomy data relevant to the investigation of the trafficking 
routes of cancer cells in preclinical mouse models. The bi-directional flow of blood in 
the TV between the PALN and SiLN gives insight into tumor cell trafficking from 
regional areas to the whole body. It is proposed that the final form of LN metastasis 
should be recognized as “LN-mediated hematogenous metastasis” based on 
lympho-venous communication. 
In Chapter 4, the surgical and non-surgical outcomes of an implanted LN tumor 
were explored, with a focus on regional cancer and distant metastasis. The 
tumor-bearing SiLN was resected to simulate clinical dissection of the sentinel lymph 
node (SLN). It was found that resection of a tumor-bearing SiLN enhanced lung 
metastasis in the mouse model. Bioluminescence imaging revealed that metastatic 
tumor cells in the down-stream LN continued to grow after the resection of the 
up-stream tumor-bearing SiLN, and that the probability of metastasis to the lungs was 
increased when the interval between SiLN inoculation and resection was reduced. 
Furthermore, histological analysis demonstrated that latent cancer cells in the lungs 
were stimulated to grow after resection of the SiLN. Fluorescence imaging indicated 
that the route of tumor cell dissemination from the SiLN to the lungs was via the venous 
system enveloping the SiLN. This part of the thesis confirmed two trafficking routes in 
the SiLN region: one towards the PALN via the LV, which is related to PALN 
 xi 
 
lymphogenous metastasis, and the other towards the venous system via the TV, which is 
related to hematogenous metastasis to distant sites. The resection of a SiLN inoculated 
with tumor cells led to an accelerated growth of metastatic tumor cells in the lungs and 
ipsilateral PALN. This result is a timely reminder of the clinical risk of iatrogenic 
induction of regional and distant cancer metastases. This phenomenon provides new 
insights into the concept of “LN-mediated hematogenous metastasis” and is the starting 
point for tracing the activation process of distant dormant cancer cells. 
In Chapter 5, it is concluded that the lymphatics can facilitate cancer cell 
dissemination, and that this is fundamental to the occurrence of cancer metastasis. 
Presently, two contrasting models are used to explain the formation of distant organ 
metastases: a lymphatic-independent hematogenous model and a lymphatic-dependent 
sequential model. The most crucial issue to resolve is whether metastatic cells come to a 
halt in LNs or continue to disseminate throughout the body by usurping either LN 
vascular vessels or efferent LVs to colonize distant organs via the blood circulation. To 
date, the detailed mechanisms involved in this important process remain a mystery. 
However, there is now little doubt that the interplay between tumors and the lymphatic 
system represents the main route used by solid cancers to spread. 
Based on a study of MXH10/Mo/lpr mice, this dissertation shows the topography of 
22 LNs and 4 peripheral lymphatic drainage routes, which can be used to explore 
peripheral lymphatic cancer metastasis in a preclinical setting. In addition, the thesis has 
clarified the communications between the lymphatic and venous systems in the axillary 
and subiliac regions, and revealed that the LV running from the SiLN to the PALN is 
capable of draining tumor cells. Moreover, the research in this thesis has also shown 
that lung metastatic foci could be rapidly activated following resection of a 
tumor-bearing SiLN. It is anticipated that this mouse model will be useful for studying 
LV imaging, lymphatic trafficking kinetics and the mechanisms of tumor-lymphatic 
system interplay during both regional and distant metastasis, with the aim of translating 
this basic research into enhanced clinical diagnosis and novel drug delivery systems. 
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1.1. Cancer metastasis 
 
Little was known about cancer until 1829 when the French surgeon, J.C.A. Récamier 
(1774-1852), gave the first clear reference to metastasis (“métastase”) in his book on 
cancer [1, 2]. At present, the accepted concept is that cancer begins when healthy cells 
change and grow uncontrollably, forming a mass called a tumor, which can be malignant 
or benign. A cancerous tumor is malignant when it can grow and spread, that is 
metastasize to other parts of the body. Metastatic neoplasia can be found in the lymph 
nodes (LNs) draining the region affected by the tumor. Metastatic lesions in LNs or 
distant organs can also arise from neoplastic blood-born emboli from tumors that are not 
located near to the nodes [3]. Metastasis is one of the hallmarks of cancer; however, the 
mechanisms underlying invasion and metastasis remain incompletely understood [4, 5]. 
Concepts of the mechanisms underlying the patterns of metastasis to different sites are 
considered in two hypotheses, namely: 1) the ‘mechanical’ hypothesis, or the physical 
dissemination of cancer cells from the primary tumor to distant sites, and 2) the ‘seed 
and soil’ hypothesis, which concerns the adaptation of these cells to foreign tissue that 
results in successful colonization [6]. The first is based on the anatomy of the routes of 
tumor cell dissemination, while the second focuses on patterns due to differential arrest 
and proliferation of cancer cells. For most cancers, the onset of metastasis involves local 
invasion of the surrounding stroma by individual cells or groups of cells that were 
originally formed in the primary tumor. After penetrating the lymphatic or vascular 
channels, the invading tumor cells can grow at the penetration site or break off either as 
single cells or as small embolic aggregates, to be transported via the circulatory system. 
Circulating tumor cells are more susceptible to host immune and non-immune defenses, 
including turbulent blood flow, monocytes, and lymphocytes called natural killer cells. 
Those tumor cells that survive these defenses usually lodge in the capillary beds of distant 
organs by adhering to capillary endothelial cells or attaching to basement membrane that 
is exposed at regions of endothelial cell retraction. Following this process, extravasation 
can occur, likely through many of the same mechanisms underlying the initial invasion. 
Growth of the metastasis in the organ parenchyma necessitates the development of a 
vascular network, evasion of the host immune system and proliferation. After reaching a 
certain size, the metastasis can give rise to many additional metastases. In this way, a 
small primary tumor can produce many metastases in a very short period of time. 
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However, only a small number of cells in the primary tumor can undertake all these steps 
and develop into metastases. The inefficiency of metastasis is accounted for, at least in 
part, by the challenge of completing the complex steps involved.  
Some of the steps in the invasion-metastasis cascade (IMC) are extremely inefficient. 
Research using experimental animal models has demonstrated that the rate-limiting step 
of the IMC is the mechanisms underlying metastatic colonization. Indeed, the attrition 
rate is usually > 99% of the cells that survive to form micrometastases (Figure 1.1).  
 
 
 
 
Figure 1.1. Inefficiency of the invasion-metastasis cascade. The figure indicates the 
approximate proportions of intravenously implanted tumor cells that die as they pass through the 
various steps of the invasion-metastasis cascade. Figure 1.1 is used with kind permission [7]. 
 
The majority of tumor cells that enter the circulation are quickly destroyed (Figure 
1.1); hence, the presence of circulating tumor cells does not necessarily predict that 
metastases will develop. The process of cancer metastasis is still difficult to predict as it 
contains stochastic elements and has sequential selective and differential proliferation 
properties. The most fearsome aspect of cancer metastasis is that conventional therapy 
cannot stop it, which ultimately leads to the death of the patient. Metastatic tumor spread 
through the blood or lymphatic vessels (LVs) occurs in most forms of cancer, and 
metastasis to regional LNs is often the single most important factor that predicts the fate 
of patients with malignant cancer [8]. Although primary tumors can be surgically resected 
or locally irradiated, it is problematic to apply these treatments to disseminated cancer. In 
many patients, metastasis may well have occurred before the primary malignant tumor 
(with the exception of skin cancers) has been diagnosed [9]. Furthermore, at the time of 
clinical diagnosis of major lesions, malignant tumors and their metastases consist of 
multiple cell populations that exhibit extensive biological heterogeneity. Such parameters 
include antigenicity, immunogenicity and rate of growth, karyotype, the cell surface 
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characteristics, susceptibility to cytotoxic drugs and, not least, the ability to metastasize 
and invade remote organs. This biological heterogeneity makes the development of 
efficacious chemotherapy extremely challenging [6].  
 
1.1.1. Lymphatic metastasis of cancer 
 
The main reason why people die of cancer is that the cancer cells spread to form 
daughter tumors, or metastases, in organs vital to life including the lungs, liver and 
gastrointestinal tract. A route frequently used by cancer cells for dissemination is the 
lymphatic system. One of the ‘mechanical’ or ‘hemodynamic’ mechanisms of metastasis 
is based on well-substantiated observations on the anatomical basis of lymphogenous 
metastatic patterns [10]. The common human cancers spread first by lymphatic 
metastasis; metastasis to the lymphatic system is the major factor predicting survival in 
patients with epithelial malignancies. Metastasis along lymphatic pathways occurs in 
stages, which may usefully be described as: pre-metastatic invasion; approach; 
penetration; translocation; intra-nodal settling; growth and destruction of the LN; and 
then subsequent metastasis to further nodes [1, 11]. Unusual patterns of lymphogenous 
metastasis have been accounted for by perturbations in lymphatic flow, which was 
suggested by Virchow (1845) and emphasized by von Recklinghausen (1885) as the 
concept of “retrograde lymphatic embolism” [12, 13]. 
In the majority of human cancers, the lymphatic vasculature acts as the main conduit 
for metastasis of tumor cells to local LNs [14-17]. Moreover, the status of the LNs is an 
important criterion used in the staging, prognosis and treatment of a variety of solid 
tumor types. However, although it is recognized that tumor-associated LVs play a key 
role in cancer progression, there is a paucity of information regarding the molecular and 
cellular mechanisms directing metastasis to the LVs. Tumor cells gain access to the 
lymphatic vasculature by invading pre-existing LVs at the margin of the tumor or by 
stimulating lymphangiogenesis [18-20]. It has been reported that malignant tumor cells 
may make an active contribution to the induction of peri-tumoral and intra-tumoral 
lymphangiogenesis in some types of cancer [20, 21]. The lymphatic system provides an 
important conduit for the maintenance of tissue fluid homeostasis and the transportation 
of macromolecules and immune cells into the circulating blood, and has been implicated 
in cancer metastasis [22, 23]. Several studies have shown that the expression of vascular 
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endothelial growth factor (VEGF)-C/D stimulates tumor-associated lymphangiogenesis 
and tumor spread to the LNs [24-30]. Research has indicated that lymphangiogenesis 
plays a role in both LN metastasis and distant metastasis, and also influences 
disease-free survival (DFS) [31]. The factors implicated as being relevant to the 
metastasis of four common types of cancer (breast cancer, colorectal cancer, lung cancer 
and melanoma) include the expression of growth factors and/or receptors that promote 
lymphangiogenesis, the tumor lymphatics and lymphatic invasion. In melanoma, the 
intratumoral lymphatics have been linked to distant metastasis [32], with a poor DFS 
[33]. In colorectal cancer, high LV density is a predictor of disease recurrence and is 
associated with LN and distant metastasis [34-36]. In lung cancer, lymphatic invasion is 
related to an increased risk of regional LN involvement in non-small-cell lung cancer 
(NSCLC), and is a predictor of distant metastasis, long-term survival of the patient and 
DFS [37-39]. In breast cancer, the expression of VEGF-C is connected with LN 
metastasis [40], distant metastasis and a shorter overall survival (OS) time [41, 42]; 
similar correlations have not been observed in other studies [43, 44]. However, the 
mechanism involved in the trafficking of tumor cells from LNs to distant organs still 
remains enigmatic (Figure 1.2). 
There is increasing evidence that has highlighted a role for the CC chemokine 
receptor-7 (CCR7) in cancer metastasis [45-47]. Although peritumoral LVs are believed 
to be functional, the significance of LVs present within a tumor remains contentious. 
Several studies have suggested that LVs enable the process of metastasis by providing a 
conduit for the dissemination of tumor cells [48]. Nevertheless, the mechanisms by 
which tumor cells cross into the lymphatic system remain unclear, and it is not known 
whether this occurs via intra-tumor lymphatics or functional lymphatics around the 
tumor [49]. There is evidence in a melanoma model that cancer cells can induce 
lymphangiogenesis or some form of lymphatic sprouting in the region of their periphery 
[50]. 
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Figure 1.2. Remodeling of lymphatic vessels in cancer and its contribution to metastasis. 
The lymphatic vessels present in adults arise during embryonic development. In cancer, these 
pre-existing lymphatic vessels undergo various types of remodeling, including 
lymphangiogenesis (which generates new lymphatics) and lymphatic enlargement (which does 
not produce new vessels, and can involve proliferative or non-proliferative mechanisms). Tumor 
lymphangiogenesis and/or lymphatic enlargement (in and around the primary tumor) are 
stimulated by growth factors that are derived from tumor cells or immune cells in the 
microenvironment of the tumor. These growth factors also promote lymphangiogenesis of lymph 
nodes, enlargement of collecting lymphatics that drain the tumor (both proximal and distal to 
sentinel lymph nodes), and changes in the lymphatic smooth muscle cells (LSMCs) around the 
collecting lymphatics. These processes are believed to promote the occurrence of metastasis. 
The mechanism by which tumor cells spread from lymph nodes to distant organs is currently 
speculative. Figure 1.2 is used with kind permission [31]. 
 
In comparison to blood vessels, the LV pathway provides numerous advantages for 
the invasion and transportation of pre-metastatic cells or embolism, just as it does for 
white blood cells, such as: 1) a discontinuous basement membrane and loose 
inter-cellular junctions; 2) an orders of magnitude slower flow rate that promotes cell 
survival by reducing shear stress; and 3) a 1,000 fold higher lymph concentration of 
hyaluronic acid, which confers cell protection and pro-survival effects [51]. The 
lymphatic system has several features suited to the transport of cells throughout the 
body while maintaining their survival and functions, including long residence times, 
areas in which flow stagnates, and access to the circulating blood through high 
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endothelial venules. Epithelial tumors (including melanoma, breast cancer, prostate 
cancer and head and neck cancers) exploit the ability of the lymphatic system to 
transport cells, and thus spread preferentially via the LVs rather than via a 
hematogenous route (for which the success rate for metastasis is extremely low, due to 
the toxicity of the serum, high shear stresses and mechanical trauma). Metastasis may 
be initially confined to the lymphatic system; however, the presence of discrete 
extra-nodal metastases indicates embolic spread through the bloodstream [45, 52, 53]. 
 
1.1.2. Hematogenous metastasis of cancer 
 
The blood vessels are an important route for cancer metastasis and it is well known 
that tumor cells can be detected in the blood of patients with cancer in the early stages 
of tumorigenesis. There are two paradigms of this dissemination: the first is a parallel 
progression model, which states that early during the formation and growth of a primary 
tumor (e.g., cancer of the breast), cells are shed by the tumor and then circulate in the 
bloodstream; the second is a conventional linear progression model, in which the spread 
of tumor cells that causes the formation of a metastasis is a delayed process in tumor 
development [52-56]. 
New insights have emerged regarding the pathways that cancer cells take once they 
have left the primary tumor. Several concepts have been developed concerning the early 
seeding of metastases in the parallel progression model, the self-seeding of a primary 
tumor by circulating tumor cells, and the formation in distant organs of premetastatic 
niches.  
One method by which cancer cells can reach distant regions is by transportation in 
the blood, followed by exiting the vasculature by the process of extravasation [57]. 
Recent work indicates that some circulating cancer cells that survive might return to the 
primary tumor rather than extravasate [58]. An alternative view is that tumor cells can 
enter the lymphatics and be conveyed to regional LNs, where (in principle) they can 
either adhere and form metastases, reach the bloodstream through high endothelial 
venules, or pass through the lymphatic system to the bloodstream via anastomoses such 
as the thoracic duct [59, 60] (Figure 1.3). 
Metastatic spread may therefore follow two models that complement each other but 
place emphasis on different routes of dissemination. In one model (Figure 1.2), cancer 
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cells spread during the early stages of tumor growth from the primary tumor to the LNs 
or the blood stream. The disseminated tumor cells (DTCs) proliferate and generate solid 
metastases in LNs, while tumor cells that spread via the blood to distant sites either 
become dormant or are destroyed. In the later stages, tumor cells spread from the 
metastases established in the LNs, and can form solid metastases in remote organs. The 
ability to do this may be acquired when cells are selected in the LN milieu. As a 
consequence, the metastasis of a tumor to other organs depends on the existence of LN 
metastases. In the other model (Figure 1.4), cells spread frequently via the blood from 
the primary tumor to distant regions, where they evolve into explicit metastases without 
having traversed the LNs [61]. 
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Figure 1.3. Routes for the development of metastasis. (a) Schematic diagram illustrating 
the possible pathways that tumor cells could follow as they travel through the body. Cancer 
cells disseminating from the primary tumor can directly enter the bloodstream. If the cancer 
cells enter the lymphatic system, they might embed in lymph nodes and develop as lymph node 
metastases. Alternatively, the tumor cells might enter the bloodstream, for example via the 
thoracic duct or high endothelial venules (HEV). Disseminated tumor cells that reach the 
bloodstream and survive might either self-seed the primary tumor, re-enter the lymphatic system 
or extravasate into organs. Cancer cells spread to the blood by metastases might also 
contribute to self-seeding. (b) Diagram showing the possible fates of disseminated cancer cells. 
After the cancer cells have extravasated and invaded vital organs, there are 3 possible 
outcomes: death, dormancy, or growth as metastases. Several factors, such as those illustrated 
in Figure 1.3, have been suggested to regulate dormancy. ECM, extracellular matrix. For 
further details, see main text. The color figure is available online at wileyonlinelibrary.com, and 
is used here with permission [60]. 
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Figure 1.4. Models of metastasis. Tumor cells can spread from the primary site via 
lymphatic (red arrows) and hematogenous (blue arrows) routes. Secondary hematogenous 
dissemination from overt metastases to other distant sites may also occur (black arrows). In the 
first model, tumor cells disseminate and proliferate in the lymph nodes to form solid metastases, 
whereas tumor cells at distant sites either die or enter dormancy. At later stages, tumor cells 
spread from metastases established in the lymph nodes to form secondary metastases at distant 
sites. This ability may be gained as the cells develop in the environment of the lymph node. As a 
consequence, the metastasis of the tumor depends on the existence of lymph node metastases. 
Hematogenous dissemination can occur from the primary tumor, from lymph node metastases 
or from distant metastases. In the second model, tumor cells disseminate predominantly via the 
hematogenous route to form metastases at distant sites. This type of dissemination may be seen 
in patients (such as those with breast cancer) who develop metastases in other organs while the 
lymph nodes remain tumor free. Hematogenous dissemination appears to begin at the early 
stages of tumor progression. Figure 1.4 is used with permission [61].  
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Accordingly, the prognosis of patients with carcinoma, even those with small 
primary tumors, is mainly determined by the hematogenous spread of tumor cells from 
the primary tumor to more distant organs (such as the bone marrow, liver, lungs or 
brain) and the subsequent outgrowth of these cells in their new microenvironment [5, 60, 
62]. However, DTCs and micro-metastases can remain in a dormant state for several 
years after complete resection of a primary tumor before giving rise to overt metastases 
[63]. DTCs derived from such metastases can re-circulate through the bloodstream and 
colonize other distant organs, giving rise to secondary metastases. Interestingly, animal 
experiments suggest that DTCs converted into circulating tumor cells (CTCs) can even 
return to the primary tumor, a process termed “tumor self-seeding” or “cross-seeding,” 
and give rise to aggressive metastatic variants [58]. It is difficult for CTCs to survive the 
effects of fast flowing blood and the immune system. The CTCs may try to adhere to 
platelets to form clumps that give them some protection. This may also help the cancer 
cells to be filtered out in the next capillary network they come across, so that they can 
migrate into the surrounding tissues [64]. These CTCs thereby have the potential to 
contribute to the development of local relapses, although this provocative hypothesis 
requires support from studies in both animals and human patients with cancer. 
 
1.1.3. Iatrogenic metastasis of cancer 
 
Iatrogenic metastasis of cancer cannot be independent of tumor cell dissemination 
through vascular vessels. Cancer cells are easily seeded during an operation or clinical 
diagnostic procedure. For example, primary tumor resection, regional resection of the 
lymphatics and fine needle aspiration (FNA) are significant opportunities for tumor cells 
to come into contact with ruptured micro-vessels and lymphatics, which will eventually 
allow them to gain access to the systemic circulation. These cells may then lodge in 
organs such as the lung or liver, which are favorable environments that promote the 
development of the seeded cells into a tumor [65]. Another relevant point is that the 
majority of patients with colorectal cancer present at a stage when the primary cancer can 
be resected with curative intent. However, despite the high resectability rate, about 
30-50% of these patients subsequently develop metastatic disease. In these patients, 
neoplastic cells would have been disseminated either before the operation or during 
surgery to remove the primary cancer. Due to the lack of appropriate detection systems, 
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the extent of pre- and intra-operative hematogenic tumor cell dissemination has not yet 
been determined [56]. Moreover, there have hitherto been no attempts to differentiate 
metastasis initiated by invasive medical interventions from the naturally occurring spread 
of malignancy. The risk of iatrogenic metastasis needs to be readdressed by the use of 
both animal models and human clinical investigations. It is proposed in this thesis that an 
animal model of metastasis can be used to investigate the relationship between sentinel 
LN (SLN) resection and lung cancer metastasis, as this would be a helpful first step 
toward determining whether the resection of tumor-bearing LNs is a risk factor for the 
distant dissemination of cancerous cells.  
 
1.1.4. Mechanisms of cancer metastasis 
 
An improved understanding of the biochemical processes underlying cancer 
metastasis, including the regulation of the mechanisms by which tumor cells invade 
local tissues and disseminate to distant sites, will facilitate the implementation of better 
therapies. Over the years, many hypotheses have been put forward to try to describe the 
inefficiency of the metastatic process, but none of these completely explains current 
biological and clinical observations [66]. Generally, most cancers must first invade and 
spread through local vessels at the primary site, allowing intravascular extension and 
systemic transport. Furthermore, the organ-specific capacity of certain cancer cells to 
attach, invade and proliferate is poorly understood, and little is known about how the 
interactions of tumor cells with various host factors determines the fate of the 
trafficking cells [6, 67]. Investigation of the factors regulating metastasis began in 1889 
when Paget examined the postmortem data of women who had died of cancer, and 
observed a high frequency of metastasis to the ovaries as well as differing incidences of 
bone metastasis for different primary tumors. Paget deduced that the distribution of 
metastases to the organs was not simply due to chance, and proposed that metastases 
develop only when there is compatibility between the “seed” (tumor cells with the 
ability to metastasize) and the “soil” (organs that are colonized and provide growth 
advantages to the seeds). There are three principles to the current “seed and soil” 
hypothesis. First, tumors are biologically heterogeneous; second, the metastatic process 
is very selective, and favors the growth and survival of a small subpopulation of cells 
that pre-exist in the heterogeneous parent tumor; and third, the outcome of metastasis is 
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the consequence of numerous interactions between metastatic cells and homeostatic 
factors [6]. In other words, metastasis is not a random process but is influenced by 
factors independent of vessel anatomy, blood flow, and the number of cancer cells 
reaching each organ. Most malignant cancers exploit the homeostatic mechanisms to 
obtain a growth advantage, with neoplastic angiogenesis as a good illustration of this. 
The French surgeon, Henry LeDran (1684–1770), first postulated that in its earliest 
stages, cancer starts as a local disease, before spreading initially to the LNs and then to 
the bloodstream. He stressed that cancer was a local lesion during the early stages and 
spread via the lymphatics. LeDran noted that LN involvement made curative treatment 
far less likely. This theory offered the hope that surgical intervention might be curative 
if it was performed sufficiently early [68, 69]. Before that time, the widely accepted 
model had originated in Greek philosophy, and suggested that cancer was the local 
manifestation of a systemic disease [70]. Around 1840, the German doctor Virchow, 
who is considered to be the father of pathology, proposed that LNs filter particles from 
the lymph, and filter out cancer cells as a first line of defense. If the LN ‘filters’ become 
saturated, they themselves can act as nidi for dissemination of cells to the next line of 
defense, and eventually to the skeleton and vital organs. Radical mastectomy was 
introduced in the 19th century on the basis of these proposals, and this therapeutic 
approach was adopted worldwide until the late 20th century as the default strategy for 
treating breast cancer. It was at this point that the concept of tumor dormancy with an 
interrupted growth paradigm was assumed as a working hypothesis to explain the 
phenomenon of metastasis. It is hypothesized that besides spreading, the primary tumor 
exerts some kind of homeostatic effect on distant metastases, which results in an 
inhibition of proliferation and/or an enhancement of apoptosis. Some investigations 
have shown that most DTCs appear to be in a dormant (i.e., non-proliferating) state [71]. 
As described in a model proposed for breast cancer [72] as well as other cancers [73], 
metastatic tumors can either grow continuously or sojourn in two dormant states, named 
S1 and S2. Orderly transition between these two dormant states eventually results in the 
progressive appearance of clinical metastases. This supports the idea that the presence 
of the primary tumor may exert some kind of homeostatic influence on distant 
metastases by mechanisms that have not yet been elucidated, ultimately causing an 
inhibition of proliferation and/or an enhancement of apoptosis. It is suggested that 
before surgery, the primary tumor somewhat restrains the S1→S2 and S2→M 
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transitions, causing the dormancy of single cells and vascular micro-metastases. In 
contrast, surgical removal of the primary tumor may in itself have a triggering effect. So 
far, the characteristics of the primary tumor responsible for the early release of cells into 
the circulatory or lymphatic systems remain unclear. The phenomenon of “tumor cell 
dormancy,” which refers to the time from tumor cell dissemination until the 
development of clinically overt metastases, is poorly understood. 
 
1.2. Lymphatic network 
 
1.2.1. What is the lymphatic system? 
 
The lymphatic system is an intricate network of vessels, nodes and tissues, including 
the spleen and thymus, which circulates lymph, a protein-containing fluid. Lymph 
slowly leaks out of the blood as it circulates throughout the body. The lymph removes 
hazardous substances from the blood, and these substances are filtered and entrapped in 
the LNs. The lymph is transported slowly around the body, and it ultimately re-enters 
the heart to be circulated once again. Macroscopically, the lymphatic system is a ‘linear’ 
network of LVs and secondary lymphoid organs, which contrasts with the ‘circular’ 
arrangement of the blood vascular system. In mammals, the two vascular systems are 
closely related [74] and together ensure that there is effective circulation: the blood 
vessels deliver oxygen and nutrients; while the lymphatic system transports fluid and 
macromolecules from tissues back to the bloodstream for recirculation, and facilitates 
the function of the protective immune system.  
Interstitial fluid is collected by the initial lymphatic capillary plexus, flows from 
pre-collector LVs to larger collecting LVs, and is returned to the circulating blood via 
lymphatic trunks or ducts. Collecting LVs are covered with smooth muscle cells and 
contain luminal valves, which help to maintain the unidirectional flow of lymph. The 
deep LVs run alongside arteries and veins. The lymphatic system also serves as a route 
for intestinal lipid absorption and the transportation of lymphocytes and 
antigen-presenting dendritic cells (the term “dendritic cells” was coined in 1973 by 
Steinman and Cohn) to regional LNs [75]. Plasma constituents, extravasated white 
blood cells and particulate matter (such as bacteria) enter the LVs through valve-like 
openings and travel through a successive number of LNs. Moreover, many malignant 
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tumors take advantage of the lymphatic vasculature for their further dissemination. In 
summary, the lymphatic system contains a linear network of vessels that transport a 
fluid, LNs that act as filters to remove impurities and harmful substances, organs such 
as the spleen that act in the production, storage and regulation of white blood cells, and 
the bone marrow from which the blood cells originate. 
 
1.2.2. Research methods used to investigate the lymphatic system  
 
Histological preparations of intact organs seldom reveal LVs; hence, various 
methods have to be employed in order to visualize the macro-anatomy of the lymphatic 
system. Vivisection in dogs fed appropriate markers was an early method used by Aselli 
(1627) to demonstrate the lymphatic system. Mercury injection is a notable method that 
was introduced by Anton Nuck (1692) and used for three centuries by anatomists. 
Mercury disperses in the luminal structures of cadavers after being injected into the skin. 
The injected mercury reaches the collecting LVs in the subcutaneous tissue through 
lymphatic capillaries in the dermis. In the past, technical difficulties existed with regard 
to distinguishing small veins from LVs without magnification, because the injected 
mercury can be trapped by both types of vessel [76]. After the use of mercury became 
obsolete in the early 20th century because of toxicity, Gerota’s method (1896) became a 
potential replacement [77]. In this technique, a mixture of colored oil paint and ether was 
injected into the skin. However, due to similarities with the mercury injection method, it 
also inevitably resulted in the staining of the venous system.  
Other methodologies used to investigate the lymphatic system include but are not 
limited to: lymphatic congestion induced by ligation of the efferent lymphatics or LNs 
of any given organ; venous congestion leading to dilation of the lymphatics; a 
combination of venous and lymphatic congestion; ligation of the efferent ducts of 
certain organs which may lead to lymphatic congestion; examination of pathological 
edematous material; and in certain cases electron microscopy investigations [78].  
Lymph flow can also be observed with the aid of fluorescently labeled 
macromolecules [79]. This technique is commonly known as ‘micro-lymphangiography’ 
and can be used for clinical diagnosis [80]. In preclinical studies, quantitative 
assessments of lymphatic uptake and interstitial mechanical properties (such as 
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hydraulic conductivity and bulk elastic modulus) have been made in the skin of the 
mouse tail [81]; these parameters are related to lymphatic uptake [82]. 
In the clinic, the investigation of lymphatic system pathology has been problematic 
due to the complex anatomy of the lymphatics [83]. Bipedal lymphography [84] is a 
lymphatic imaging approach introduced several decades ago that enabled radiologists 
and clinicians to visualize previously undetectable lymphadenopathy. The advance of 
noninvasive approaches such as lymphoscintigraphy, ultrasound, computed tomography 
(CT), positron emission tomography (PET), magnetic resonance imaging (MRI) and 
optical imaging has greatly facilitated the assessment of LNs [85]. 
Nowadays, emerging and newly evolved modalities such as photoacoustic imaging 
and nanotechnology are replacing these traditional techniques [86]. The combination of 
novel modalities with comparatively traditional approaches has guided us towards new 
developments in the diagnosis and therapeutic monitoring of tumor progression in the 
lymphatic system, and in targeted drug delivery systems. 
 
1.2.3. Embryology of the lymphatic system 
 
Despite being first described centuries ago, the lymphatic vasculature remained 
relatively poorly characterized until recently, when several lymphatic-specific molecular 
markers were identified [87]. During phylogenesis, an independent lymphatic system was 
first developed by vertebrates [88]. In mammals, LVs originate from embryonic veins to 
form an independent and unidirectional network of vessels that communicate with blood 
vessels at a small number of specific sites [89]. Blood vessels are generated during 
embryonic development through two distinct processes: vasculogenesis and angiogenesis 
[90]. Vasculogenesis describes the de novo construction of vessels by angioblasts 
(endothelial precursor cells), while angiogenesis describes the generation of a more 
elaborate and complex network of vessels through the growth and remodeling of 
pre-existing blood vessels [91]. LV development occurs secondarily to that of blood 
vessels. A recent study employing a lineage tracing approach [92] has substantiated the 
suggestion made by Sabin (1902) more than a century ago, and confirmed that the 
lymphatic vascular network originates from the embryonic veins. The development of the 
lymphatic vasculature occurs in a stepwise manner [49], and in the mouse begins in the 
anterior cardinal vein at around embryonic day 9.75 [92, 93]. In recent years, some of 
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the mechanisms regulating the various stages of this process have been elucidated [49, 
87, 91, 94]. Embryologically, the lymphatic system is derived from the mesenchymal 
clefts that form after the fifth week of gestation, and the LVs develop in close proximity 
to the veins. 
 
1.2.4. Composition of the lymphatic system 
 
The lymphatic system may be considered to comprise a fluid (lymph), vessels that 
transport this fluid, and organs that contain lymphoid tissue. The lymphatics are present 
in the skin and in all viscera except avascular structures (for example, cartilage, hair, 
nails and epidermis); certain vascularized structures such as the spinal cord, retina and 
bone marrow also lack LVs. Lymph collector vessels are present on the surface of the 
dura mater in the epineuria, in peripheral nerves fibers and in the periosteum [95]. 
Lymph is a fluid that has a composition similar to that of the blood plasma. Lymph 
originates from blood plasma that has passed through the walls of capillaries at their 
arterial end; the accumulating interstitial fluid is collected and removed by tiny LVs, 
and eventually returned to the circulating blood. Once the interstitial fluid has entered 
the lymphatic capillaries, it is known as lymph. The return of this fluid to the 
bloodstream helps to prevent edema and maintain normal blood volume and pressure. 
Lymph fluid consists of chyle, proteins, fat and white blood cells (predominantly 
lymphocytes).  
LVs are found in nearly every organ and blood vessel-containing interstitial tissue 
and serve as a drainage system for excess fluid and large molecules, or for cells that 
cannot easily find their way back into venules [96]. The LVs are thin, fragile structures 
that become thicker as they penetrate deeper into tissues. They consist of three layers: 
an external (connective tissue) layer, a middle (smooth muscle and elastin) layer and an 
internal (endothelial cell) layer. Unlike the blood vascular system, LVs only transport 
fluid away from the tissues. The lymphatic system has six main types of conduit: 
capillaries, pre-collectors, collecting vessels, LNs, trunks and ducts. The sizes of these 
range from 10 μm to 2 mm in diameter [82]. The smallest LVs are the microscopic 
lymphatic capillaries, which arise in the tissue spaces as initial or terminal blind-ended 
sacs. Lymphatic capillaries exist in all regions of the body, with the exception of the 
central nervous system, bone marrow, and tissues (such as the epidermis) that lack 
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blood vessels. The lymphatic capillary wall is composed of a single layer containing 
endothelial cells, typically comprised of one or two non-fenestrated and highly 
attenuated cells. LVs are anchored to the extracellular matrix by very thin (4–10 nm) 
fibrillin-containing filaments, which are inserted into the plasma membranes of the 
endothelial cells. These anchoring filaments prevent the collapse of the vessels when 
interstitial pressure is elevated [22]. The squamous cells are arranged in an overlapping 
manner to form a simple one-way valve, which allows fluid to enter the capillary but 
prevents lymph from leaking out of the vessels. The lymphatic capillaries merge to form 
LVs. Small LVs combine to form larger tributaries, known as lymphatic trunks, which 
drain large areas. In turn, the lymphatic trunks merge to form the two lymphatic ducts. 
The right lymphatic duct drains lymph from the upper right quadrant of the body, and 
the thoracic duct drains the rest. Similar to veins, these lymphatic conduits have thin 
walls and contain one-way valves to aid lymph propulsion and prevent retrograde flow. 
The lymphatic system lacks a central pump (analogous to the heart in the cardiovascular 
system), thus flow occurs at a low Reynolds number (i.e., without significant inertia) 
[97]. The pressure gradients that propel the lymph through the vessels arise from 
contraction of skeletal muscle, respiratory movements, and contraction of smooth 
muscle in the vessel walls. 
Lymphatic organs contain groups of lymphocytes and other cells (such as 
macrophages) embedded within a network of short, branching connective tissue fibers. 
The lymphocytes originate (along with other types of blood cell) in the red bone marrow, 
and are transported to the lymphatic organs by the blood. Lymphocytes make an 
important contribution to the immune response that aims to destroy invading organisms. 
On encountering microorganisms or other foreign substances, lymphocytes proliferate 
within the lymphatic organs and migrate via the bloodstream to the site of the invasion. 
The lymphatic organs comprise the LNs, tonsils, spleen and thymus.  
LNs are bean-shaped structures usually no more than 2.5 cm in length. LNs are 
widely distributed along lymphatic pathways throughout the body, although they are not 
found in the central nervous system. The LNs filter the lymph before it is returned to the 
bloodstream. LNs tend to cluster at three superficial regions on each side of the body: 
the inguinal nodes in the groin, the axillary nodes in the armpit, and the cervical nodes 
in the neck. Typically, a LN is encased by a capsule of connective tissue, and is 
subdivided into compartments known as lymph nodules that are separated by spaces 
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known as lymph sinuses. The lymph nodules contain dense aggregates of lymphocytes 
and macrophages. The afferent lymphatics, which transport lymph into the LN, enter the 
node on the convex side at different parts of its periphery. The lymph traverses the 
lymph sinuses to enter an efferent LV located at an indented region known as the hilum; 
the efferent LV carries lymph away from the LN.  
The three groups of tonsils consist of clusters of lymphatic tissue found beneath the 
mucous membranes lining the nose, buccal cavity and pharynx. The pharyngeal tonsils 
are found close to the opening of the nasal cavity into the pharynx. When they become 
enlarged, these tonsils are known as adenoids and can interfere with breathing. The 
palatine tonsils are found near the opening of the oral cavity into the pharynx. The 
lingual tonsils are positioned on the posterior surface of the tongue, near to the opening 
of the oral cavity into the pharynx. The tonsils contain lymphocytes and macrophages 
that act to protect against harmful substances and pathogens that access the body 
through the nose and mouth.  
The spleen is found in the upper left cavity of the abdomen, inferior to the 
diaphragm and posterior to the stomach. The spleen is much larger than a LN (it is the 
largest lymphatic organ in the body), but is similar to a LN in shape and structure. The 
spleen is encased in a capsule of connective tissue that extends inward to divide the 
organ into lobules. The lobules contain two types of tissue, known as white pulp 
(lymphatic tissue comprised predominantly of lymphocytes arranged around arteries) 
and red pulp (venous sinuses containing blood and cords of lymphatic cells, such as 
lymphocytes and macrophages). Blood that enters the spleen via the splenic artery is 
filtered as it moves through the sinuses and then leaves via the splenic vein. The 
filtering of blood by the spleen is similar to the filtering of lymph by LNs. Splenic 
lymphocytes react to pathogens in the blood in order to try to destroy them, and the 
macrophages then phagocytose the resultant debris (including damaged cells and other 
large particles). Together with the liver, the spleen also removes old or damaged 
erythrocytes from circulating blood. Similar to other lymphatic tissues, the spleen 
generates lymphocytes, particularly when responding to an invading pathogen. In 
addition, the splenic sinuses act as a reservoir for blood. In pathological situations such 
as hemorrhage, blood is mobilized from the spleen into the general circulation by the 
contraction of smooth muscle in the splenic vessel walls and capsule.  
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The thymus comprises two lobes located anterior to the ascending aorta and 
posterior to the sternum. It is a soft organ that is relatively large in infants and children, 
but its size begins to decrease after puberty such that it is relatively small in adults. The 
main physiological role of the thymus is the processing and maturation of specialized 
cells known as T lymphocytes (T cells). These lymphocytes do not respond to pathogens 
and foreign agents while in the thymus. However, on maturation, these lymphocytes 
enter the bloodstream and migrate to other lymphatic organs where they contribute to 
the immunological defense against disease. The thymus also secretes the hormone 
thymosin, which induces lymphocyte maturation in other lymphatic organs. 
Broadly speaking, the composition of the lymphatic system includes efferent linear 
vessels and organs. These are integrated with capillaries supported by anchoring 
filaments in the extracellular matrix, pre-collectors, collecting vessels, trunks and ducts, 
which are interspersed with LNs and connected to other lymphatic organs such as the 
tonsils, spleen and thymus. 
 
1.2.5. Primary functions of the lymphatic system 
 
The lymphatic system has three main physiological functions. The first of these is 
the return of excess interstitial fluid to the blood in order to regulate tissue fluid balance. 
Approximately 90% of the fluid that diffuses out of a capillary is reabsorbed back into 
the capillary; the 10% that does not return adds to the interstitial fluid that bathes tissue 
cells. Small protein molecules can “leak” through the capillary wall to raise the 
interstitial fluid osmotic pressure, further inhibiting the return of fluid into the 
capillaries, and promoting the accumulation of fluid in the tissue spaces. If this process 
were to continue, the blood volume and pressure would fall, and the volume of the 
interstitial fluid would increase, resulting in edema (swelling). The excess interstitial 
fluid and proteins are collected by lymphatic capillaries and returned to the venous 
circulation.  
The second physiological role of the lymphatic system is in the absorption of fats 
and fat-soluble vitamins from the gastrointestinal tract, and the subsequent delivery of 
these to the venous blood. The mucosal lining of the small intestine has numerous 
finger-like projections known as villi, in the center of which are blood capillaries and 
specialized lymphatic capillaries termed lacteals. Most of the nutrients are absorbed into 
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the blood capillaries, but fats and fat-soluble vitamins enter the lacteals. The lymph 
within the lacteals is known as chyle, and it has a milky appearance due to the high fat 
content. 
The third, perhaps best known, function of the lymphatic system is to act as a 
holding reservoir for the body’s defenses against invading, disease-causing 
microorganisms. LNs and other lymphatic organs filter the lymph to remove foreign 
particles such as microorganisms. The lymphatic organs also house lymphocytes that 
destroy invading pathogens. It is within these ‘incubators’ that white blood cells 
proliferate; tumor cells can also proliferate here and disseminate to form metastatic 
tumors. Thus, the lymphatic system has notable advantages over the blood circulation as 
a route for drug delivery. In particular, there is great potential for the targeting of 
immune-modulators, chemotherapeutic drugs and imaging agents to specific LNs, 
thereby avoiding systemic side effects that limit drug dosages, dilution in the systemic 
circulation, and degradation by the liver [82]. 
One can summarize the primary functions of the lymphatic system into two 
categories: 1) a circulatory role, which includes returning excess tissue fluid to maintain 
normal blood volume, blood pressure and ionic concentrations, as well as collecting and 
delivering absorbed lipids from the small intestine to the blood via the left subclavian 
vein; and 2) a defensive role, which includes filtering out pathogens in LNs, producing 
and exporting lymphocytes to the vascular system, and the detection of antigens 
followed by the production of specific antibodies in various lymph organs. In the case 
of cancer, the lymphatic system carries out its functions of filtering and defense; 
unfortunately, it can be usurped and used as an incubator and network for tumor cell 
dissemination.  
 
1.3. The lymphatic network and cancer metastasis 
 
Metastatic tumor spread via the blood or LVs occurs in most types of human cancer, 
and metastasis to regional LNs is often the most important prognostic factor in patients 
with carcinoma. For most cancers, local and regional LNs are often the first site of 
metastasis. The state of the LNs in patients with cancer is critical for diagnosis, staging, 
treatment and follow-up [8]. The SLN is the first regional LN to which tumor cells 
metastasize; subsequently, further dissemination may occur to other nodes or into the 
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systemic circulation. The recent introduction of SLN biopsy (SLNB) and its 
replacement by regional LN excision in patients with melanoma or breast cancer reflects 
the current understanding of the organized nature of LN metastases [94]. 
The process of lymphatic metastasis is complex and involves many factors, 
including gene expression in the cancer and lymphatic epithelium [98], 
lymphangiogenesis in the tumor and LNs [82], and the location of the primary tumor 
relative to small LVs [99]. 
Microarray analyses of gene expression have yielded novel insights into the biology 
of metastasis [100]. Research has shown that in patients with breast cancer who were 
free of LN metastases, the clinical outcome could be predicted on the basis of the gene 
expression profile of their tumor [101]. Other investigations have suggested that gene 
expression patterns could be used to foresee outcomes in patients with both LN-positive 
and LN-negative breast tumors [102]. 
The use of in silico approaches allowed the identification of a gene expression 
profile in adenocarcinoma metastases that was evident in some primary tumors, and 
could therefore be exploited to predict which tumors were most likely to become 
metastatic [98]. Furthermore, several biomarkers have been identified in primary breast 
tumors, the levels of which were associated with the tendency of a patient to suffer a 
relapse into metastasis [7, 102]. However, these assays are prognostically informative 
only in patients with particular subtypes of breast cancer; they are unable to predict 
increased risk in patients with other subclasses of the disease [103]. 
Tumor lymphangiogenesis has been reported to exhibit a good correlation with 
metastasis. VEGF-C [104, 105] was the first growth factor shown to promote 
angiogenesis as well as lymphangiogenesis [106-108]. Human VEGF-C activates both 
VEGFR-2 and VEGFR-3 receptors to promote lymphangiogenesis and angiogenesis, 
whereas the less mature form predominantly activates VEGFR-3 receptors [109] to 
promote lymphangiogenesis [25, 110]. VEGF-C overexpression in human breast cancer 
cells (genetically engineered to be fluorescent) transplanted into nude mice led to an 
increase in the size of peritumoral LVs and a marked enhancement of intratumoral 
lymphangiogenesis, with no notable influence on tumor angiogenesis. A greater 
intratumoral LV density was found to be associated with an enhanced incidence of 
metastasis to regional LNs and the lungs. Intratumoral LV density correlated strongly 
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with the degree of lung metastasis, suggesting that the lymphatic system plays a critical 
role in the spread of tumor metastases to distant organs [110]. 
Another investigation revealed a significant effect of VEGF-D in tumor metastasis 
and lymphangiogenesis. Similar to that seen for VEGF-C, epithelioid tumors 
overexpressing VEGF-D in mice exhibited intratumoral LV formation and enhanced LN 
metastasis. Notably, the lymphatic dissemination induced by VEGF-D could be 
inhibited with a neutralizing anti-VEGF-D antibody, implying that inhibition of 
lymphangiogenesis may prove to be a valuable method for inhibiting the metastatic 
dissemination of cancer cells [27]. The findings of peritumoral and intratumoral 
lymphangiogenesis in cancer and an association of these with cancer metastasis [25, 27, 
110] have created a foundation for exploring novel approaches to the diagnosis of 
cancer and its treatment. 
Among the many anatomical relationships, the proximity of the primary tumor to 
the small lymphatics has a substantial influence on metastasis. By using 
VEGF-D-induced tumor lymphangiogenesis, it was found that initial/capillary 
lymphatics and pre-collecting lymphatics are the source vessels that sprout to form 
tumor ‘neo-lymphatics’ and that larger collecting LVs are not involved [111]. Therefore, 
variations in lymphatic subtypes located in different regions of the body may be another 
important determinant of tumor metastasis [99]. 
 
1.3.1. Sentinel lymph node and cancer metastasis 
 
The concept of a sentinel node was first described by Gould et al. in a patient with 
cancer of the parotid gland [112] and was implemented clinically on a broad scale by 
Cabanas in penile cancer [113]. The 1990s saw the clinical application of lymphatic 
mapping to individual patients with a view to predicting the lymphatic drainage of a 
tumor and identifying the SLN(s) involved, i.e. those LN(s) within the lymphatic 
drainage basin that were most likely to contain disseminating tumor cells [114]. 
Moreover, it was also suggested that a colloid inserted into breast tissue would migrate 
to the same first node as the tumor cells [115]. 
The SLNs are defined as the first echelon of LNs (one or more) that receive 
lymphatic drainage from the primary tumor, and from which tumor cells may later pass 
into non-SLNs [116]. Traditionally, the pattern of cancer metastasis in most cases was 
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interpreted using the cascade doctrine or SLN theory, which suggests that regional LNs 
are not randomly reached by lymphatic tumor cell emboli, but spread in an orderly 
fashion from the primary tumor to the SLNs [5, 117]. For example, tongue cancer may 
not only affect the organ itself, but also the regional LNs, lung, liver and diaphragm 
[118]. 
It has been stated that the SLN concept of sequential, orderly progression through 
regional afferent lymphatics is validated by the absence of metastases in ‘downstream’ 
LNs during long-term follow-up after SLNB. Hematogenous spread cannot be ruled out, 
but the relatively low frequency of distant metastases in patients with tumor-negative 
SLNs indicates that this route of metastasis is far less common [119]. In addition, the 
vast majority of solid tumors have the potential to spread to and involve the lymphatic 
system, which is then responsible for propagating distant metastases. The SLN 
represents the first node in the lymphatic system to be drained by the tumor and is 
therefore the most likely site to detect lymphatic metastases. Radiolabeled sulfur colloid 
is a frequently used agent, either alone or together with a blue dye (methylene blue or 
isosulfan blue); detection is carried out using a hand-held gamma probe or by visual 
inspection of any LNs that stained blue. Early studies revealed that the application of 
this technique, termed SLNB, to the first LNs ‘standing guard’ in the axilla achieved 
high accuracy, i.e. the SLN was positive in all but a small number of patients found to 
have positive LNs on subsequent axillary LN dissection (ALND) [58, 120]. It was 
therefore felt that a negative SLNB could make ALND unnecessary. However, whether 
‘early adoption’ of SLNB represents a good or hasty judgment remains to be determined. 
Some oncologists at National Cancer Institute-designated cancer centers, who design 
and promote clinical trials, largely eschewed the randomized National Surgical 
Adjuvant Breast and Bowel Project trial of SLNB, and even questioned whether it was 
necessary [121]. In hindsight, SLNB has proven accurate and safe and is now accepted 
as standard care [122]. The clinical trials are ongoing and are providing important data 
on SLNB while the final comprehensive outcome analysis is awaited [120]. 
 
1.3.2. Biopsy of the sentinel lymph node  
 
SLNB represents one approach to sample reliably LNs to which tumor cells have 
spread [123-127]. The SLN(s) is (are) defined as the node(s) to which drainage and 
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metastases from a major tumor first occurs. SLNB was initially developed for use in 
patients with melanoma [128], but was subsequently adapted for use in oral and other 
malignancies [129, 130], particularly breast cancer [131]. Intraoperatively, the SLN is 
detected by the uptake of a tracer that is injected into the breast (tissue or skin) and 
imitates the lymphatic spread of tumor cells [123]. The use of SLNB was originally 
restricted to small and unifocal tumors, but the indications have rapidly expanded within 
the last few years. Today, SLNB is indicated in practically all subgroups of patients 
whose LN status is unclear. Although adjuvant treatment is now more tailored by 
predictive factors, the axillary LN status is still associated with a strong prognostic 
power. Numerous decisions regarding local (radiotherapy) or systemic treatment are still 
guided by the pathological nodal status. SLNB is therefore an important diagnostic tool 
that can guide breast cancer treatment. Numerous validation trials that performed SLNB 
with a backup ALND have shown that the SLN accurately stages the axilla in patients 
who undergo surgery for primary breast cancer. A meta-analysis of more than 8,000 
patients revealed a false negative rate of only 8% [58]. SLNB provides the opportunity 
for a more detailed analysis of LN status, including serial sections and 
immunohistochemistry of one or a few SLNs. The clinical significance of a low tumor 
burden in the SLN regarding prognosis and consecutive systemic treatment is not yet 
fully understood. A recent case vignette included the therapeutic recommendation that 
patients with type IIB melanoma should undergo wide local excision with a 2-cm 
margin and concomitant SLNB under general anesthesia on an outpatient basis. If 
SLNB identifies at least one positive SLN, completion lymphadenectomy should be 
recommended after a discussion with the patient about the risk of having additional 
positive nodes. If the SLNs are negative, no additional regional surgery should be 
recommended [132]. Clinical evidence has shown that early regional LN recurrence is 
very uncommon after positive SLNB and completion lymphadenectomy. Patients with 
positive SLNs are more likely than those with negative SLNs to develop both 
local/in-transit recurrence and distant metastases within a short follow-up period [133]. 
In the future, lymphatic imaging will need to be developed further so that the technique 
can be used for cancers involving the deeper viscera, such as the gastrointestinal and 
respiratory tracts. A major challenge will be to design novel, non-invasive techniques 
for assessment of the SLN that have the same or even better accuracy than currently 
used approaches [134]. 
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1.4. Biopsy of tumor-positive sentinel lymph nodes: does it promote 
cancer metastasis? 
 
Presently, lymphatic mapping with SLNB has been considered by many institutions 
to be the standard treatment for several malignant tumors, and is the most common 
modality used for cancer staging and treatment guidance [135-137]. By analogy, 
investigating the second echelon of LNs would also be important to establish the status 
of LN metastasis [128, 138]. However, this pattern of tumor metastasis may only 
represent one side of the coin. 
The other opinion is the two-stage paradigm of metastatic spread of cancer [61]. 
During the early stages of cancer growth, tumor cells disseminate from the primary 
tumor to the lymphatics and/or blood vessels. While some of the DTCs proliferate and 
form solid metastases in LNs, others spread to distant sites via the blood vessels, and 
either die or survive to remain dormant. At a later stage, tumor cells also disseminate 
from the established LN metastases to regional and distant sites, where solid metastases 
develop. 
The dissemination of cancer cells during these early and late stages could occur in a 
non-mutually exclusive fashion. However, distant ectopic evolution of the DTCs may be 
more relevant to the clinical diagnosis and treatment of cancer [139]. According to the 
above paradigm, SLNB would not be a useful approach for assessing how far 
metastases may have spread during the early stages of cancer metastasis. More 
importantly, it is impractical to consider the lymphatic system as an independent route 
of tumor dissemination, since blood-borne DTCs can spread to distant sites in the early 
stages as a result of bypassing the LVs, and the two vascular systems are interrelated [61, 
140]. Inspired by a model that has been proposed to explain the recurrence of breast 
cancer in patients after surgical resection of their tumors [141], it is necessary to make a 
reflection on whether perturbation of tumor-bearing SLNs by SLNB may accelerate the 
activation of the latent cancer metastatic foci. 
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1.4.1. Hypothesis 
 
It is hypothesized that SLNB can alter the way in which cancer develops, and 
potentially accelerate metastasis, especially when the dissected SLNs are tumor 
positive. 
 
1.4.2. Rationale of the hypothesis 
 
The spread of cancer, following removal of the primary tumor, is influenced by 
stimulating factors generated by cancer-host-surgery interactions. Metastatic behavior 
may be affected by the interplay of various growth factors, which can influence the 
outcome of the host and their interaction with the tumor. This contrasts with the premise 
that removal of a primary tumor is a local phenomenon with no other biological 
consequences [142]. 
In the early stages of cancer, DTCs can be detected in the blood [53], and this is 
paralleled by the detection of DTCs in bone marrow taken from patients with 
early-stage cancers [60, 61]. Moreover, clinical and animal investigations have shown 
that DTCs and their stromal cells or immune cells are integrated as heterotypic clumps 
as they circulate in the blood [143-146]. The tumor cells that migrate during these early 
stages can grow independently, but most are kept dormant in the target organ until they 
are stimulated by appropriate signals. 
The micro-environmental signals and homeostatic changes that orchestrate normal 
wound healing can stimulate local or systemic tumor growth [147]. Since the 
physiology of wound healing has many common denominators with the 
non-physiological process of carcinogenesis, an effect of wound healing on tumor 
development and metastatic outgrowth would not be unexpected [148]. 
In addition, studies on the molecular mechanism of LN metastasis have indicated 
that the lymphatic milieu, which includes VEGFs, pleiotropic factors and haptotactic 
chemokine gradients, is responsible for mediating the metastasis to SLNs and beyond 
[68, 149-151]. Moreover, it has been reported that the flow of lymph, containing 
tumor-secreted lymphangiogenic factors and other metastasis-promoting chemokines, is 
driven from the tumor-positive SLNB field to distant sites via LVs, resulting in a 
pre-metastatic niche in the lung [152, 153]. 
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While LN lymphangiogenesis has been positively correlated with metastasis in 
several tumor models, it is not an event that is exclusive to malignancy. 
Lymphangiogenesis is also closely related to trauma, surgical operations and wound 
healing, as are growth factors, cytokines and chemokines [154-156]. 
Moreover, removal of the primary tumor and tumor-positive SLNs would terminate 
the release of anti-angiogenic extracellular matrix proteins into the blood, thereby 
attenuating the inhibition of distant metastatic foci that were previously dormant. There 
is evidence for such an effect in other studies; for example, angiostatin, an inhibitor of 
angiogenesis, has been reported to be directly generated by tumor tissue [157-159]. 
Similarly, thrombospondin-1, another inhibitor of angiogenesis secreted by a wide 
variety of tumor types, was lost following resection of tumor-bearing LNs [160]. 
Taking into account the effects of surgery, wound healing responses, and an 
imbalance in favor of the evolution and angiogenesis of distant tumor foci, it is 
plausible that biopsy of tumor-positive SLNs could promote cancer metastasis. 
In brief, it is proposed that ‘anchoring, evolution and angiogenesis switching’ of 
tumor cells may be a useful paradigm to explain how positive SLNB might promote 
cancer metastasis. Of note, perturbation of the SLNs during the process of SLNB may 
unwittingly deliver ‘seed’ and/or ‘soil’ to the distant tumor foci, reinforcing the 
metastatic colonies [143, 144]. 
 
1.4.3. Hypothesis evaluation and consequences 
 
Given the evidence that SLNB might accelerate both regional and remote cancer 
metastasis, it will be important to verify the hypothesis in animal models. To the limit of 
our knowledge, no substantial investigations have been carried out to verify or refute 
the iatrogenic risks of SLNB activation of distant metastatic foci in either the ‘animal 
clinic’ or real human clinical settings. 
Moreover, two randomized clinical trials are warranted to test the hypothesis. First, 
detailed evaluations of serum VEGFs, cytokine markers (CXCR4 and CXCL12) and 
pleiotropic factors are needed in two groups of patients: those who have developed a 
distant metastasis, and control subjects who are alive and have not developed a distant 
metastasis at the time of metastasis in the corresponding case. Second, a prospective, 
randomized, stage-matched, multi-institutional, observational trial is needed. The first 
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study would evaluate the potential metastasis-promoting factors generated in response 
to SLNB; the second study would evaluate outcomes to remove selection bias [161]. 
If demonstrated to be true, the present hypothesis would have an important impact 
on clinical treatment and research, and would contribute to the mounting evidence 
against LN resection biopsy. Appropriate therapeutic strategies would need to be 
developed to minimize the risk of cancer metastasis following SLNB, such as the use of 
anti-tumor immunological agents and/or anti-angiogenic drugs during the biopsy. 
 
1.4.4. Concluding remarks 
 
The statements about iatrogenic metastasis of cancer are based on clinical 
observations along with assumptions based on the review of relevant papers [162, 163]. 
If an existing theory is unable to explain clinical or experimental findings, we are 
obligated to cast doubt and make new hypotheses, which can then be tested. It appears 
that established hypotheses of metastasis may have some flaws, although the risk of 
distant metastasis following tumor-positive SLNB has yet to be generally accepted. 
From the data available, it may be inferred that tumor-positive SLNB can alter the 
development of cancer in favor of the induction of metastasis, through a combination of 
growth stimulating factors (‘the Fisher effect’) and an angiogenic signal following 
surgery (‘the Folkman effect’) [147]. If the hypothesis presented here was to be 
supported by the results of animal experiments and clinical studies, surgeons would 
have to reconsider using SLNB until an effective approach is found that can offset the 
risk of iatrogenic tumor metastasis. 
 
 
1.5. Thesis objectives   
 
The main objective of this thesis was to clarify the relationship between cancer 
metastasis and the lymphatic system in a preclinical mouse model of cancer metastasis, 
with the aim of extrapolating the data to the clinical study of oncology. In chapter 1, an 
overview was provided on the subjects of cancer metastasis, the lymphatic system and 
clinical metastasis of oral cancer. The consensus among the world’s leading 
investigators is that the lymphatics can facilitate the dissemination of cancer cells, 
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which is fundamental to the occurrence of cancer metastasis. To understand the 
mechanisms involved, preclinical models of LN metastasis will be essential for the 
elucidation of tumor cell trafficking processes, and will be fundamental for the design of 
new techniques to diagnose and treat the serious consequences of LN metastasis. 
However, the identification of LNs and LVs in mice using conventional imaging 
modalities is challenging, since the LN diameter in normal mice is only 1–2 mm. In 
chapter 2 of this thesis, the aim was to identify the LNs and LVs in MXH10/Mo/lpr 
inbred mice, which exhibit systemic swelling of LNs that reach up to 10 mm in diameter. 
Moreover, the peripheral inter-LN vessels were studied with the aim of inducing cancer 
locally by regional lymphatic metastasis, as this approach could potentially be used in 
the design of new techniques for the diagnosis and treatment of LN metastasis. 
Metastatic tumor cells in the lymphatic system disseminate to distant organs after 
entering the venous system. However, the communication routes between the lymphatic 
and venous systems have not been fully elucidated in mice. In chapter 3 of this thesis, 
these communication routes have been established, with a focus on the anatomy of the 
communications between the lymphatic and venous systems in the axillary and subiliac 
regions of the mouse. Furthermore, peripheral blood vessels were studied with a focus 
on blood flow in the thoracoepigastric vein (TV), which is believed to be relevant for 
the dissemination of cancer cells to distant sites. 
Iatrogenic induction of regional and distant cancer metastases is a potential risk 
associated with clinical resection of tumor-positive SLNs. However, there have been no 
studies of this risk in a mouse model of cancer metastasis. In chapter 4 of this thesis, the 
consequences of resecting a tumor-bearing subiliac lymph node (SiLN) were studied in 
mice. The experiments were designed to analyze the correlation between dissection of a 
tumor-positive LN (simulating dissection of a tumor-positive SLN) and regional and 
distant metastasis.  
In chapter 5, a conclusion was made on the roles of the lymphatics, cancer cell 
dissemination and cancer metastasis. Moreover, based on experimental data and a 
relevant literature review, it is postulated that tumor-positive SLNB risks promoting 
cancer metastasis. This hypothesis is supported by the parallel tumor dissemination 
theory, the ‘soil and seed’ theory (vide supra), and current knowledge of the 
mechanisms underlying angiogenesis and dormant tumor foci, which are closely related 
to the data presented in chapters 2, 3 and 4. 
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The research objectives of this thesis are an important component of the preclinical 
study of lymphatic cancer metastasis. It is envisaged that, in the not too distant future, 
the research findings will be translated into safer clinical diagnostic procedures and 
lymphatic-targeted therapies for cancer and its metastasis. 
This dissertation describes transdisciplinary research covering preclinical oncology 
and biological engineering. The reproducibility of the lymphatic topography, 
lymphatic-venous communication and activation of macroscopic metastatic foci after 
tumor-bearing LN ressection in mice are providing the groundwork for preclinical 
research on cancer metastasis imaging and the development of novel drug delivery 
systems. 
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CHAPTER 2 
 
 
Lymphatic mapping of mice with systemic 
 lympho-proliferative disorder:  
usefulness as 
an inter-lymph node metastasis model of cancer 
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2.1. Summary 
 
Preclinical models of LN metastasis are fundamental for the study and design of 
new techniques for the diagnosis and treatment of LN metastasis. However, the 
identification of LNs and LVs in mice is challenging with conventional imaging 
modalities, since the LN diameter in normal mice is 1-2 mm. Here I describe 
MXH10/Mo/lpr inbred mice, which develop systemic swelling of LNs up to 10 mm in 
diameter, allowing investigation of the topography of LNs and LVs. Using a gross 
anatomy dissection approach, 22 different LNs situated in the head and neck, limbs, 
thoracic and abdominal regions were found. Furthermore, four peripheral inter-LN 
vessels were found: the SiLN to the PALN; the parotid LN to the caudal deep cervical 
LN; and the popliteal LN to both the sciatic LN and the SiLN. Metastasis to the PALN 
via LVs was induced by inoculating FM3A/Luc mouse breast cancer cells into the SiLN. 
The results demonstrate that the MXH10/Mo/lpr mouse strain is an excellent model in 
which to investigate lymphatic drainage and inter-LN metastasis of cancer. This 
research unveils the anatomy of murine lymphatics to give new insights into the 
investigation of inter-LN metastasis of cancer, especially the mechanisms involved in 
the trafficking of cancer cells in the inter-LN vessels. The results provide data that will 
very useful in the quest to develop better lymph drainage-based drug delivery systems. 
 
2.2. Introduction  
 
LN metastasis is an extremely important factor for defining the prognosis of cancer. 
Various imaging modalities have been used to diagnose early LN metastasis, including 
computed tomography (CT), magnetic resonance imaging (MRI), positron emission 
tomography (PET) and ultrasound [164]. However, a diagnostic imaging procedure has 
yet to be developed that can accurately diagnose metastasis to LNs that are less than 10 
mm in diameter. In previous studies, our laboratory demonstrated that the combined use 
of high frequency ultrasound and ultrasound contrast agents enabled the visualization of 
small blood vessels in cancer, a potentially useful method for the early diagnosis of 
cancer [165]. In addition, a LN metastasis model was developed using an 
MRL/MpJ-lpr/lpr (MRL/lpr) strain of mouse [166], which does not express the Fas 
gene involved in apoptosis [167, 168]. At three to four months of age, the LNs in these 
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mice are enlarged to approximately 10 mm in diameter, a size similar to that found in 
humans. Furthermore, proliferation of nascent tumor blood vessels could be analyzed 
from the start of cancer metastasis after the inflow of tumor cells from the afferent 
lymphatic vessel (LV) to the LN. Thus, this metastasis model is very well suited to the 
development of the next generation of ultrasound imaging modalities for the detection 
of early LN metastasis.  
The MRL/lpr strain of mouse shows LN swelling throughout its whole body at three 
to four months of age [169, 170]. In addition, MRL/lpr mice spontaneously develop 
glomerulonephritis, vasculitis, arthritis and sialadenitis, which are similar to human 
collagen diseases, at the same age that they exhibit LN swelling [171]. Since the 
glomerulonephritis of MRL/lpr mice becomes fatal at five months, their period of use in 
LN metastasis experiments is limited.  
In previous work, our group established recombinant inbred strains of MXH/lpr 
mice by intercrossing MRL/lpr and C3H/HeJ-lpr/lpr (C3H/lpr) strains; these were used 
for the analysis of susceptibility genes associated with a number of important diseases 
[172]. From these recombinant inbred strains of mice, a sub-line of MXH10/Mo/lpr 
mice was found to be unique; the sizes of most of the peripheral LNs were as large as 10 
mm at only 2.5 to 3 months of age; furthermore, both the size and the time of onset of 
the LN swelling were consistent and predictable. Moreover, these mice did not develop 
severe glomerulonephritis and vasculitis, compared with MRL/lpr mice, and thus their 
life span was longer than that of MRL/lpr mice. Consequently, breeding and 
maintenance of the MXH10/Mo/lpr mice was found to be easier than that of MRL/lpr 
mice, and based on these attributes, it was determined that these mice would be suitable 
for various studies of murine lymph networks, especially in the field of experimental 
exploration of LN metastasis [173].  
 Lymphatic mapping is generally considered to be critical for investigations of LN 
metastasis. In order to make better use of the MXH10/Mo/lpr mouse as a model of LN 
metastasis, it is necessary to understand the anatomical locations, nomenclatures and 
lymphatic drainage routes between upstream and downstream LNs. In previous reports, 
the anatomical locations and nomenclatures of murine LNs have often been ignored and 
even assigned incorrectly [174-176]. Due to confusion about the anatomical locations 
and names of LNs, there is great scope for misinterpretation of mouse lymphatic 
network data obtained by different research groups. Indeed, Van den Broeck and 
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colleagues [177] have noted misuse of the anatomical names of the LNs of mice in 
previous publications. These authors examined the anatomical locations of the LNs of 
the BALB/cAnNCrl strain of mouse, and reported their anatomical nomenclature. In 
order to visualize mouse LNs that were difficult to identify macroscopically, the 
investigators injected dye and adjuvant into tissue near the LNs, using 12 different 
protocols, and identified 22 different LNs [177]. However, when my laboratory 
conducted experimental studies on the lymph network using these protocols, their 
procedures seemed to complicate the investigations and became unnecessary factors that 
adversely affected the experimental results.  
 In the present study, I have examined the anatomical locations, sizes and 
nomenclatures of the LNs of MXH10/Mo/lpr mice, and the peripheral lymphatic 
drainage routes between upstream and downstream LNs. In addition, based on the 
results obtained, the development of cancer metastasis between LNs was explored. 
 
2.3. Materials and Methods  
 
2.3.1. Mice 
 
All in vivo studies involving mice were carried out in strict accordance with the 
recommendations in the Guide for Proper Conduct of Animal Experiments and Related 
Activities in Academic Research and Technology, 2006. The protocols were approved 
by the Institutional Animal Care and Use Committee of Tohoku University, Japan. All 
anatomical dissection was performed under sodium pentobarbital anesthesia, and great 
efforts were taken to minimize animal suffering. 
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2.3.2. Characteristics of MXH10/Mo/lpr mice 
 
The MXH10/Mo/lpr mouse strain is a substrain of the recombinant inbred strain of 
the MXH/lpr mouse [178]. MXH/lpr mice were generated using two different parental 
inbred strains as progenitors, MRL/lpr (major histocompatibility complex, MHC; H-2
k
) 
and C3H/lpr (H-2
k
), followed by an F1 intercross and more than 20 generations of strict 
brother-sister mating. The MXH/lpr mice were bred under specific pathogen-free 
conditions in the Animal Research Institute, Graduate School of Medicine, Tohoku 
University.  
In order to use MXH10/Mo/lpr mice as a model to study LN metastasis, the average 
weights of the proper and accessory axillary LNs from the bilateral axillary regions 
were measured. Since the glomerulonephritis and renal vasculitis of MRL/lpr mice 
becomes fatal by the age of five months, the period for which they may be used for 
experiments on LN metastasis is limited. Therefore, the histopathology of renal lesions 
in the MXH10/Mo/lpr mice was also examined. Histological examinations of 18 to 21 
week-old MXH10/Mo/lpr mice were carried out using light microscopy, allowing 
evaluation of glomerulonephritis and renal vasculitis. Pathological scores for 
glomerulonephritis and renal vasculitis were determined according to previously 
defined pathological criteria [179]. Briefly, the vasculitis score was defined as the 
highest score of all the arterial lesions observed: the scoring system denotes normal as 0, 
destruction of the external elastic lamina as 1, and severe lesion with intimal thickening 
as 2. The glomerulonephritis score was defined as the average of the scores measured 
from 50 glomeruli: the scoring system denotes normal as 0, cell proliferation or 
infiltration as 1, membranoproliferation, lobulation or hyaline deposition as 2, and 
crescent formation or global hyalinosis as 3. 
 
2.3.3. LN mapping 
 
Three MXH10/Mo/lpr mice were used for this part of the study. Mice were placed 
under deep general anesthesia using 2.5% isoflurane in oxygen (Abbott Japan Co., Ltd., 
Tokyo, Japan) using an inhalation gas anesthesia system designed for small laboratory 
animals, and peripheral LNs were surgically exposed and carefully measured and 
characterized. The mice were then euthanatized by an overdose of diethyl ether. Caudal 
 38 
 
deep cervical, intra-thoracic and abdominal LNs were harvested in the proper sequence. 
All the separated LNs were located, classified and measured, as documented in Table 
2.1 
 
2.3.4. Emulsion dye casting of peripheral lymph drainage routes 
 
Four MXH10/Mo/lpr mice were used in these experiments. Mice were placed under 
general anesthesia using 2.5% isoflurane in oxygen. The SiLN or the popliteal LN was 
perfused separately (i.e. 1 in each mouse) with an aqueous emulsion of acrylic resin. 
100 μL of the emulsion dye (1 mL cadmium orange medium, Soft type, Bonny Co., 
Tokyo, Japan; 4 mL Liquitex, latex chloroprene 671A, Binney & Smith, Easton, PA, 
USA; 5 mL 0.9% normal saline) was injected into the SiLN or popliteal LN at a velocity 
of 50 μL/min, using a 27-gauge standard double-wing needle and an injection depth of 3 
to 5 mm. Following this procedure, mice were euthanized with an overdose of diethyl 
ether and stored overnight at 4C. The next day, mice were necropsied and the lymph 
drainage routes were carefully traced with the aid of a surgical microscope (Leica M165 
C, Wetzlar, Germany) and camera (C-5060, Olympus, Tokyo, Japan). 
 
2.3.5. Fluorescence imaging of peripheral lymph drainage routes 
 
Two MXH10/Mo/lpr mice were used for fluorescein isothiocyanate (FITC) 
lymphography of head and neck peripheral drainage routes. Mice were placed under 
deep general anesthesia with 2.5% isoflurane in oxygen, and the peripheral LNs of the 
neck were surgically exposed. 50 μL of 0.5 mM FITC dye (21877-1G-F; Sigma, St. 
Louis, MO, USA) was injected, at a velocity of 50 μL/min, into the superficial parotid 
LN using a 27-gauge standard double-wing needle [180]. Immediately after this 
injection, images were obtained with the aid of a fluorescence stereomicroscope 
(M165FC, Leica). 
A pair of MXH10/Mo/lpr mice was used for indocyanine green (ICG) 
lymphography of peripheral body and limb lymph drainage routes. 30 μL of 125 μg/mL 
ICG solution (excitation: 805 nm; emission: 840 nm; Daiichi Pharmaceutical, Tokyo, 
Japan) was injected separately into the SiLN or popliteal LN of each mouse, at a 
velocity of 10 μL/min, using a 27-gauge standard double-wing needle. Fluorescence 
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images of subcutaneous lymphatic drainage were recorded immediately after injection, 
using a Photodynamic Eye or PDE system (PDE; Hamamatsu Photonics, Hamamatsu, 
Japan) [181].  
 
2.3.6. Cell culture 
 
C3H/He mouse mammary carcinoma cell line (FM3A) cells [182] were obtained 
from the Cell Resource Center for Biomedical Research, Institute of Development, 
Aging and Cancer, Tohoku University. The cells have a histocompatibility of H-2k, 
which is the same as that of MXH10/Mo/lpr mice. FM3A/Luc cells, stably expressing 
the firefly luciferase gene, were electroporated into FM3A with pGL4.51 (Invitrogen, 
Carlsbad, CA, USA) using a Gene Pulser Xcell (Biorad, Hercules, CA, USA) with 
settings of 300 V and 25 F. FM3A cells were maintained in RPMI-1640 medium 
(Biological Industries, Haemek, Israel) supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin. FM3A/Luc cells were cultured in RPMI 1640 
medium, supplemented with 10% FBS, 1% penicillin/streptomycin and 1 mg/mL 
geneticin (G418 sulfate, Sigma-Aldrich). Cells were incubated at 37°C in a mixture of 5% 
CO2 and 95% air until 80% confluence was achieved. Cells were routinely verified by 
morphological and growth characteristics by labeling them with Trypan blue. Cells were 
tested for Mycoplasma contamination on the day of the inoculation, day 0, using a 
MycoAlert Mycoplasma Detection Kit (Lonza Rockland, Inc., Rockland, ME, USA), 
according to the manufacturers protocol. Only Mycoplasma-negative cells were used in 
the present study [183]. 
 
2.3.7. Induction of metastasis in the PALN 
 
Four MXH10/Mo/lpr mice were used in the next series of experiments. Metastasis 
to the PALN was induced by injecting 1.5 × 10
6
 FM3A/Luc cells, suspended in 30 μL of 
a mixture of 10 L PBS and 20 L of 400 mg/mL Matrigel (Collaborative Biomedical 
Products, Bedford, Canada), into the SiLN under the guidance of a high-frequency 
ultrasound imaging system (Vevo770; VisualSonics Inc., Toronto, Canada), which used 
a 40 MHz transducer (RMV-704; VisualSonics Inc.) [184]. Metastasis to the PALN was 
analyzed using an in vivo bioluminescence imaging system (IVIS; Xenogen, Alameda, 
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CA, USA) [183]. Each mouse was anesthetized with 2% isoflurane in oxygen, and 
luciferin (150 mg/kg; Promega Co., Madison, WI, USA) was administered by 
intraperitoneal injection. 10 min after injection, luciferase bioluminescence was 
measured for 30 s, using the IVIS; this procedure was carried out on days 6, 10, 14, 16 
and 18 post-inoculation, with the day of inoculation defined as day 0. To demonstrate, 
convincingly, metastasis in the PALN, we also analyzed ex vivo fluorescence. The flank, 
which included the PALN and lymphatic vessels, was dissected (under deep anesthesia) 
on day 18 and placed on a 100 mm culture dish. After the observations were made, mice 
were euthanatized by administering an overdose of ether.  
 
2.3.8. Histological analysis 
 
All the harvested samples were fixed overnight in 18.5% formaldehyde in PBS at 
4°C (Rapid Fixative, Kojima Chemical Industry, Inc., Saitama, Japan), dehydrated and 
embedded in paraffin. The embedded specimens were cut into 2 - 4 μm serial sections, 
and either stained with hematoxylin and eosin (HE) or immunostained for detection of 
LYVE-1-positive and CD31-positive cells. Immunostaining of vascular endothelial cells 
was achieved by incubation with a pre-diluted rabbit anti-CD31 polyclonal antibody 
(1/100 dilution; sc-1506-R, Santa Cruz Biotechnology, Inc., Santa Cruz, California, 
USA) for 2 h, followed by the use of an anti-rabbit IgG Histofine MAX-PO (R) kit 
(Nichirei Biosciences Inc., Tokyo, Japan) for 16 min at room temperature. 
Immunostaining of lymphatic endothelial cells was performed using a rabbit anti-mouse 
LYVE-1 polyclonal antibody (4 μg/mL, 103-PA50AG, Cosmo Bio Co. Ltd., Tokyo, 
Japan) for 2 h, followed by an anti-rabbit IgG Histofine MAX-PO (R) kit for 16 min at 
room temperature. The specimen boundary was determined under low magnification, 
using a microscope (BX51; Olympus) connected to a digital camera (DP72; Olympus). 
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2.3.9. Statistical analysis 
 
 Data are expressed as the mean ± SD where indicated. Statistical differences were 
analyzed using the Kruskal–Wallis test and the Mann–Whitney U-test. Values of P < 
0.05 were considered to be indicative of statistical significance. 
 
2.4. Results 
 
2.4.1. Weight of LNs 
 
In order to use the MXH10/Mo/lpr mice as a model to study LN metastasis, the 
average weight of their LNs was measured. The mean weight of the proper and 
accessory axillary LNs from the bilateral axillary regions of the MXH10/Mo/lpr mice 
was 0.862 ± 0.256 g (mean ± SD, n = 8), compared with a value for MRL/lpr mice of 
1.095 ± 0.372 g (mean ± SD, n = 22). 
 
2.4.2. Pathological scores for glomerulonephritis and renal vasculitis 
 
When compared with MRL/lpr mice, microscopic examination of the kidneys of 
MXH10/Mo/lpr mice exhibited greatly reduced signs of glomerulonephritis and renal 
vasculitis. The pathological indexes for glomerulonephritis and vasculitis also appeared 
to be different between the MRL/lpr and MXH10/Mo/lpr strains. In the present study, 
the glomerulonephritis and vasculitis scores of the MXH10/Mo/lpr mice were 0.55 ± 
0.45 (mean ± SD, n = 8) and 0.38 ± 0.75 (mean ± SD, n = 8), respectively. This 
compares with previously reported [179] glomerulonephritis and vasculitis scores in 
MRL/lpr mice of 1.84 ± 0.45 (mean ± SD, n = 9) and 1.44 ± 0.72 (mean ± SD, n = 9), 
respectively. These results indicate that glomerulonephritis and renal vasculitis were 
less severe in MXH10/Mo/lpr mice than in MRL/lpr mice. Consequently, the breeding 
and maintenance of MXH10/Mo/lpr mice was easier than that of MRL/lpr mice, and 
usefully the life span of the former was significantly longer. 
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2.4.3. Harvesting and mapping of LNs 
 
A total of 22 LNs were detected in the MXH10/Mo/lpr mice on the basis of gross 
anatomy, and the mapping of these LNs is shown in Figure 2.1. The LNs were divided 
into 3 categories: peripheral (head and neck region, forelimb, hindlimb; No. 1–9), 
intra-thoracic (No. 10–12), and intra-abdominal (No. 13–22), as shown in Table 2.1. 
The categories were designated according to the necropsy investigation and previous 
reports of the topography and nomenclature of BALB/cAnNCrl mice [177]. A new term 
has been used to describe the caudal deep cervical LN (No. 4), since the position of this 
LN was lower than that previously described by Van den Broeck et al. [177]. 
 
 
Figure 2.1. Schematic drawing of the locations of the lymph nodes (LNs) in an 
MHX10/Mo/lpr mouse. The numbers (1–22) relate to the descriptions given in Table 2.1. 
Figure 2.1 is used with permission. 
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2.4.4. Peripheral lymph drainage routes 
 
Peripheral lymph drainage routes may be used in the identification of metastatic 
tumor cells, and also for the development of drug delivery systems and imaging 
modalities. An aqueous emulsion of acrylic resin was injected into each peripheral LN 
to locate the drainage routes. Four drainage routes were detected: (a) a LV from the 
SiLN to the PALN; (b) a LV from the superficial salivary LN to the caudal deep cervical 
LN; (c) LVs from the popliteal LN to both the sciatic LN and the SiLN.  
 
2.4.4.1. LV from the SiLN to the PALN 
 
Figure 2.2A shows the anatomical positions of the SiLN and the PALN, 24 h after 
injection of acrylic resin into the SiLN; the upstream LN was the SiLN (U) and the 
downstream LN the PALN (D). Figure 2.2Aa indicates the locations of the SiLN and the 
PALN, as well as the lymphatic drainage route between them, while Figure 2.2Ab 
reveals the efferent LV of the SiLN (U). Figure 2.2Ac shows the afferent LV of the 
PALN, and Figure 2.2Ad demonstrates the bifurcation of the afferent LV to the PALN. 
The resin in the LV terminated at two points; two parts (p1, p2) were dissected along the 
broken line shown in the figure to include each of these points. Figure 2.2Ae shows the 
resin in the efferent LV from the dissected PALN (p1), and Figure 2.2Af shows the resin 
drained from p1, detected in the subclavian vein. In order to establish the direction of 
the LV from the SiLN to the PALN, ICG was injected into the SiLN. Figure 2.2B 
presents data obtained from dynamic imaging of the LV from the SiLN (U) to the PALN 
(D), with images captured 150 s after injection of ICG; these images confirmed flow 
from the SiLN to the PALN. Next, it was confirmed that the resin had been injected into 
the LV between the 2 LNs. First, as a control, HE staining was used to observe 2 LVs 
running parallel to the superficial epigastric vein (Figure 2.2Cb). Then, India ink was 
injected into the SiLN, and the labeling confirmed that both LVs filled with the ink 
(Figure 2.2Cd). In the experiments, several types of LV branches between the SiLN and 
PALN were identified: (i) a single LV; (ii) one LV which diverged from the main vessel 
and ran parallel to it; and (iii) one LV which diverged from the main vessel, ran parallel 
to it and then rejoined it (data not shown). 
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Figure 2.2. Lymph vessel (LV) from the subiliac lymph node (SiLN) to the proper axillary 
lymph node (PALN). (A) Anatomical mapping of the inter-lymph node (LN) vessel between the 
SiLN and the PALN. (a) Location of the SiLN (U), the PALN (D) and the LV drainage route 
between them. (b) Efferent LV of the SiLN (U). (c) Afferent LV of the PALN. (d) Bifurcation of 
the afferent LV to the PALN (D). The resin in the LV terminated at two points. Two parts (p1, p2) 
were dissected along the broken line to include each point. (e) Resin in the efferent LV from the 
dissected PALN (p1). (f) Resin drained from p1, detected in the subclavian vein. (B) Flow of 
ICG from the SiLN (U) to the PALN (D) via the LV. The images were captured 150 s after 
injection of ICG into the SiLN. U: SiLN; D: PALN; LV: lymph vessel. (C) Identification of the 
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LVs between the SiLN and PALN (n = 2). (a) & (b) show controls; (c) and (d) were treated with 
India ink. India ink was injected into the SiLN to identify the LVs connected to the PALN. (a) & 
(c) are bright-field images, (b) & (d) show hematoxylin/eosin staining. The broken lines indicate 
the cross-section of the harvested tissues. Two LVs ran parallel to the superficial epigastric vein, 
and two LVs filled with India ink. Figure 2.2 is used with permission. 
 
2.4.4.2. LV from the superficial salivary LN to the caudal deep cervical LN 
 
A schematic drawing of the lymphatic structure within the peripheral head and neck 
region is shown in Figure 2.3A. Figure 2.3B shows the anatomical structure of the 
para-salivary LNs (highlighted in the figure with a broken line), where U indicates the 
superficial parotid LN. The lymphography of the efferent LV from the superficial 
parotid LN, obtained by injecting FITC solution into the superficial parotid LN, is 
shown in Figure 2.3C. The assumption was made that the FITC solution drained to the 
caudal deep cervical LN.  
 
2.4.4.3. LVs from the popliteal LN to both the sciatic LN and the SiLN 
 
Figure 2.4A illustrates the anatomical locations of the popliteal LN, the sciatic LN 
and the SiLN, 24 h after injection of resin into the popliteal LN; the upstream LN was 
the popliteal LN (U), with the sciatic LN (D1) and SiLN (D2) downstream.  
Figure 2.4Aa shows the left lateral recumbent position revealing the right-side 
popliteal LN (U) and the drainage vessel (LV1) to the sciatic LN (D1). Figure 2.4Ab 
shows the supine position, revealing the right-side popliteal LN (U). There were two 
efferent lymphatic vessels (LV1, LV2) from the popliteal LN (U): one was to the sciatic 
LN (D1), medial to the gluteus superficialis muscle, as indicated by the dotted area; the 
other was to the SiLN (D2), which was found in the fold of the flank (plica lateralis) 
cranial to the thigh musculature, as indicated by the circled area. Figure 2.4Ac 
demonstrates the efferent LV (LV2) of the popliteal LN (U) to the SiLN (D2), with the 
right-side femur harvested. Figure 2.4Ad shows the efferent LV (LV3) of the popliteal 
LN (not shown) bypassing the sciatic LN (D1) and draining into the intra-abdominal LN. 
In order to establish definitively the directions of the drainage routes from the popliteal 
LN, ICG was injected into the popliteal LN (U) (Figure 2.4B). Figure 2.4Ba is a 
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schematic drawing of the hind leg of the mouse, while Figure 2.4Bb shows the drainage 
route from the popliteal LN (U) to the sciatic LN (D1), as revealed by ICG imaging. 
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Figure 2.3. Lymph vessel (LV) draining from the superficial salivary lymph node (LN) to 
the caudal deep cervical LN. (A) Schematic drawing of the lymphatic structure of the 
peripheral head and neck region; U indicates the superficial parotid LN. (B) Anatomical 
structure of the para-salivary LNs, denoted by the broken line; U indicates the superficial 
parotid LN. (C) Lymphography of the efferent LV of the superficial parotid LN, following 
injection of fluorescein isothiocyanate (FITC) solution into the superficial parotid LN. It was 
assumed that the FITC solution drained to the caudal deep cervical LN. 
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Figure 2.4. Lymph vessel (LV) from the popliteal lymph node (LN) to both the sciatic LN 
and the subiliac LN (SiLN). (A) Anatomical location of the popliteal LN (U), the sciatic LN (D1) 
and the SiLN (D2), revealed 24 h after injection of resin into the popliteal LN (U). The upstream 
LN was the popliteal LN, while the sciatic LN (D1) and SiLN (D2) were downstream. (a) Left 
lateral recumbent position showing the right-side popliteal LN (U) and the drainage vessel (LV1) 
to the sciatic LN (D1). (b) Supine position showing the right-side popliteal LN (U). Two efferent 
LVs (LV1, LV2) to the sciatic LN (D1, medial to the gluteus superficialis muscle, indicated by 
the dotted area) and the SiLN (D2, in the fold of the flank cranial to the thigh musculature, 
indicated by the circle) were characterized. (c) Efferent LV (LV2) from the popliteal LN (U) to 
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the SiLN (D2), with the right-side femur harvested. (d) Efferent LV (LV3) of the popliteal LN 
(not shown) bypassing the sciatic LN (D1) and draining to the intra-abdominal LN. (B) LVs 
from the popliteal LN to both the sciatic LN and the SiLN. (a) Schematic drawing of the hind leg 
of a mouse. (b) Indocyanine green imaging of the drainage route from the popliteal LN (U) to 
the sciatic LN (D1). The other anatomical drainage routes could not be simultaneously detected. 
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2.4.5. Induction of metastasis from the SiLN to the PALN 
 
As described above, four routes were identified that were intimately involved in 
peripheral lymphatic drainage. Among these, the LV from the SiLN to the PALN was 
considered to be superior for accessibility and ease of observation, and traversed a 
relatively long distance between the two LNs with no branching networks. Whether this 
LV could be used as a drainage route for tumor cells was therefore investigated. Tumor 
cells were injected into the SiLN to induce metastasis to the PALN. Figure 2.5A shows 
the in vivo bioluminescence signals detected in the PALN on days 14, 16 and 18 after 
inoculation of cells into the SiLN. To confirm metastasis, the flank was dissected, which 
included the SiLN, PALN and LV between them, on day 18. Ex vivo bioluminescence 
signals were detected (using the IVIS) in both the SiLN and the PALN (Figure 2.5B). 
Figures 2.5Ca and 2.5Cb show metastatic tumor cells in the marginal sinus of the LN 
forming a tumor mass, with the growth expanding into the cortical area.  
Figures 2.5Cc and 2.5Cd identify LYVE-1-positive cells in the serial section shown 
in Figure 2.5Ca. Tumor cells were observed in the lymphatic sinuses, involving the 
marginal (upper) and medullary (lower) sinuses. Figures 2.5Ce and 2.5Cf show 
CD31-positive cells in a serial section of the tissue shown in Figure 2.5Ca. Cell 
numbers appeared to be increased in the paracortical and medullary areas of the LN, 
possibly indicating a response to the site of tumor metastasis. The cells were also 
detected in the marginal sinus, suggesting angioneogenesis in the tumor mass.  
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Figure 2.5. Induction of metastasis from the subiliac lymph node (SiLN) to the proper 
axillary lymph node (PALN), via lymph vessels (LVs). (A) Progression of metastasis 
demonstrated by in vivo bioluminescence imaging. (B) Ex vivo bioluminescence signals. The 
flank, which included both lymph nodes (LNs) and the LV between them, was dissected on day 
18 and placed on a 100-mm culture dish. (C) Histological findings. (a, b) Metastatic tumor cells 
(meta) were observed in the marginal sinus of the LN, forming a tumor mass with growth 
expanding into the cortical area (hematoxylin/eosin staining). (c, d) LYVE-1-positive cells 
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(lymphatic endothelia) in a serial section corresponding to (a). The cells were observed in the 
lymphatic sinuses, involving the marginal (upper) and medullary (lower) sinuses 
(immunostaining). (e, f) CD31-positive cells (vascular endothelia) in a serial section 
corresponding to (a). Cell numbers seem to be increased in the paracortical and medullary 
areas of the LN, possibly in response to tumor metastasis. Cells were also detected in the 
marginal sinus, suggesting angiogenesis in the tumor mass (immunostaining). Figure 2.5 is used 
with permission. 
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2.5. Discussion 
 
Accurate identification of LNs in mice is critical for studies of tumor metastasis, and 
of regional immune responses following immunization. However, these small lymphatic 
organs are often difficult to identify in mice using standard dissection techniques. 
Consequently, rats (which are larger) have been used to characterize rodent lymphatic 
drainage, although there are distinct differences between species [185, 186]. The LNs of 
the rat have been classified into somatic nodes, which drain the skin and underlying 
musculature, and visceral nodes that drain primarily the thoracic, abdominal and pelvic 
organs. Somatic nodes generally lie external to skeletal muscle in subcutaneous or 
areolar tissue, or in fossae between the muscle masses. These nodes have been 
sub-divided functionally into peripheral and central groups. The peripheral group drains 
skin and musculo-skeletal sites only. The central group drains similar anatomical areas 
but also receives lymphatic channels from peripheral nodes [186]. Murine LNs have 
been intensively studied with various in vivo staining approaches using inks, dyes and 
adjuvant injection methods. In one investigation of murine LNs, 13 lymph centers were 
identified, including 16 LNs; in addition, two peripheral drainage routes (the popliteal 
LN to the external sacral LN, and the subiliac LN to the deep axillary LN) were 
identified [187]. In a descriptive study of the BALB/cAnNCrl mouse, 22 different LNs 
were found, which were topographically mapped and named [177]. 
In the present study, 13 MXH10/Mo/lpr male mice expressing systemic 
lymphadenopathy were used, with some peripheral LNs being as large as 10 mm in 
diameter. The location and size of 22 LNs were characterized using gross anatomical 
techniques (n = 3, Table 2.1). Furthermore, 4 peripheral drainage routes were identified 
using resin and fluorescent dyes (n = 6); these routes included LVs that drained from the 
SiLN to the PALN (Figure 2.2), from the superficial parotid LN to the caudal deep 
cervical LN (Figure 2.3), and from the popliteal LN to both the sciatic LN and the SiLN 
(Figure 2.4). These LNs and drainage routes have been recognized as somatic central 
nodes and lymphatic channels, as defined in rats by Tilney [186].  
One of the drainage vessels that is described here, from the SiLN to the PALN, has 
been observed consistently in previous studies in rats and mice [185-187]. Furthermore, 
this lymphatic route has been investigated for tumor-cell shedding and tracking [188, 
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189]. Since anatomical variations sometimes occur, it is speculated that the peripheral 
drainage routes may also show variation.  
In general, lymphatic metastasis is a multi-step process requiring initial peri-tumoral 
lymphangiogenesis, invasion and transport, tumor homing, and subsequent proliferation 
of the tumor within the LNs [190]. The exploration of cancer metastasis in 
MXH10/Mo/lpr mice was designed to simulate LN metastasis: FM3A cells with 
Matrigel were injected into the SiLN, as a secondary onset model of cancer, to induce 
inter-LN metastasis to the PALN. The cells that had grown in the SiLN were detected by 
bioluminescence imaging 6 days after inoculation (Figure 2.5A), and had disseminated 
to the PALN 8 days later. Pathological findings demonstrated that tumor cells were 
present in the marginal sinus and continuously invaded the cortical regions (Figure 
2.5C). This progression of metastasis is similar to the natural process by which cancer 
metastasis proceeds. The induction of metastasis in the present experiments probably 
depended on two main factors: tumor growth and increased interstitial pressure in the 
SiLN, respectively [191].  
The limitation of the present lymph node metastasis model is that the model cannot 
simulate the initial stage when tumor cells enter into the lymphatics Moreover, when 
inoculation of the SiLN is carried out, technical aspects such as the LN puncture site, 
the injection velocity, and operator skill are critical for the establishment of the 
inter-lymph node metastasis model.  
In all chapters, the method used for the injection of contrast agent into the LN was 
optimized to minimize the risk of dye entering the blood vessels. All the experimental 
mice were under general anesthesia during the procedure, and the LNs were exposed 
directly with the aid of a surgical microscope (Leica M 165C, Wetzlar, Germany) and 
mounted camera (C-5060, Olympus, Tokyo, Japan). 
The solution was injected through a 27-gauge standard double-wing needle (Terumo 
Co., Tokyo, Japan), either manually (for India ink and aqueous emulsion of acrylic resin) 
or automatically with a driven syringe pump (fluorescence solution), at a rate of 50 
μL/min or 100 μL/min respectively. The injection depth, which was half the longest 
diameter of the LN, ranged from 3 to 5 mm. 
In conclusion, 22 LNs and 4 peripheral drainage routes were identified in 
MXH10/Mo/lpr mice. Furthermore, it was demonstrated that the LV running from the 
SiLN to the PALN has the potential to drain tumor cells. It is anticipated that this mouse 
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model will be useful for studying the mechanisms of LN metastasis, lymphatic 
trafficking kinetics, LV imaging and lymphatic drug delivery systems. 
The significance of the inbred mouse strain that has been developed and the 
relevance of the lymphatic investigation carried out is that this research will not only 
deepen our understanding of the pathological anatomy of mouse lymphatics, but also 
lay the groundwork for future exploration of cancer metastasis mechanisms to LNs in 
mice. Furthermore, by exploiting the peripheral lymphatics of the mouse, cancer 
metastasis has been successfully simulated in LNs, opening up an exciting avenue of 
future research.  
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Table 2.1. LNs characterized in MXH10/Mo/lpr mice 
†Nomenclature and ‡location were based on the description of Van den Broeck et al. [177].  
We coined a new name for the caudal deep cervical LN (no. 4) since the position of this LN was lower than that described by Van den Broeck et al. [177]. No. 1 - 9: 
peripheral (head and neck region, forelimb, hindlimb) LNs; no. 10 - 12: intra-thoracic LNs; no. 13 - 22: intra-abdominal LNs; LN no. 11 - 16 and LN no. 21 are isolated. 
The LNs no. 17 are merged together, and are counted as one. LNs other than those above are located bilaterally and symmetrically
 
NO English name Topography Size (Mean±SD) (mm) (n=3) 
1 Mandibular ln. Rostromedial to the sublingual and mandibular salivary glands. 10.8±1.1 
2 Accessory mandibular ln. Dorsolateral to the mandibular lymph node. 7.3±0.7 
3 Superfacial parotid ln. Cranioventral to the parotid gland.salivary gland. 10.3±1,1 
4 Caudal deep cervical ln. Caudal-medial to sternocephalic m., lateral to sternohyoid m, muscle (m.). 6.7±0.5 
6 Proper axillary ln. Medial to the shoulder, dorsolateral to ascending pectoral m. 8.8±0.4 
5 Accessory axillary ln. Lateral to cutaneous truncim. 8.7±0.7 
7 Subiliac ln. In the fold of the flank (plica lateralis) cranial to thigh musculature. 9.7±0.9 
8 Sciatic ln. Medial to gluteus superficialis m., caudal to gluteus.medius m. 6.5±1.0 
9 Popliteal ln. Behind the knee, between the adductor muscle and the semimembranous muscle. 10.3±0.9 
10 Cranial mediastinal ln. Lymph nodes located lateral to the thymus. 6.8±1.6 
11 Tracheobronchal ln. Lymph node at the tracheal bifurcation. 8.7±0.5 
12 Caudal mediastinal ln. Lymph node in the caudal mediastinum.ventral to the esophagus. 4.7±0.5 
13 Gastric ln. Single (unpaired) lymph node in the lesser omentum at the minor curvature of the stomach. 4.7±0.5 
14  Pancreaticoduodenal ln. Single (unpaired) lymph node in the mesoduodenum, dorsal to the portal vein, surrounded by pancreatic tissue. 3.7±0.5 
15 Jejunal ln. Large cluster of lymph nodes in the mesojejunum along the cranial mesenteric artery. 5.7±0.5 
16 Colic ln. In the mesocolon at the transition between ascending colon and transverse colon. 9.3±0.5 
17  Caudal mesenteric ln. Single (unpaired) lymph node in the caudal mesentery at the origin of the caudal mesenteric artery. 38.7±1.7 
18 Renal ln. Dorsal to the ipsilateral kidney nearby the renal blood vessels, caudal to the adrenal gland. 8.7±0.7 
19 Lumbar aortic ln. Lateral to (and adjacent with) the abdominal aorta, halfway between the origin of the renal and common iliac arteries. 6.5±0.5 
20 Lateral iliac ln. In adipose tissue caudolateral to the kidney along the deep circumflex iliac artery. 4.7±0.5 
21 Medial iliac ln. Major bilateral lymph node at the terminal segment of the abdominal aorta and the origin of the common iliac artery. 3.7±0.5 
22 External iliac ln. Small lymph node along the initial (intra-abdominal) segment of the external iliac a., before the latter enters the femoral canal. 
5.3±0.5 
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CHAPTER 3 
 
 
Communication between lymphatic and venous 
systems in mice 
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3.1. Summary 
 
The lymphatic system in mice consists of lymphatic vessels and 22 types of lymph 
node. Metastatic tumor cells in the lymphatic system spread to distant organs through 
the venous system. However, the communication routes between the lymphatic and 
venous systems have not been elucidated fully. Here, the communication routes 
between the lymphatic and venous systems are identified in the axillary and subiliac 
regions of MHX10/Mo/lpr inbred mice, which develop systemic swelling of lymph 
nodes up to 10 mm in diameter, allowing investigation of the topography of the lymph 
nodes and lymphatic vessels. Using a gross anatomy dissection approach, the efferent 
lymphatic vessels of the proper axillary lymph node were shown to communicate with 
the subclavian vein. Furthermore, it was found that the thoracoepigastric vein, which 
connects the subclavian vein and inferior vena cava, runs adjacent to the subiliac and 
proper axillary lymph nodes, and receives venous blood from these lymph nodes 
routed through small branches. The direction of blood flow in the thoracoepigastric 
vein occurred in two directions in the intermediate region between the proper axillary 
lymph node and subiliac lymph node; one to the subclavian vein, the other to the 
inferior vena cava. These data reveal the anatomy of the communication between the 
lymphatic and venous systems in the axillary and subiliac regions of the mouse, and 
provide new insights relevant to the investigation of the mechanisms of lymph node 
metastasis and cancer immunology, and the development of diagnostic and treatment 
methods for lymph node metastasis, including drug delivery systems.  
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3.2. Introduction 
 
The lymphatic system plays a crucial role in immune surveillance and fluid 
homeostasis as well as in tumor formation and metastasis progression. The lymphatic 
system is somewhat different from the cardiovascular system in that it is a 
blind-ended network, and the flow in the system is unidirectional and not driven by a 
central pump (i.e. the heart). The flow of lymph eventually communicates with the 
venous system. As a result, tumor cells that enter the lymphatic system can 
communicate with the venous system. Therefore, elucidation of the communication 
routes between the lymphatic and venous systems is essential for the investigation of 
metastatic mechanisms and clinical treatment strategies. However, the anatomy of the 
communication routes between the lymphatic and venous systems has not been fully 
investigated in animal experiments. One reason has been the lack of a noninvasive 
imaging system capable of monitoring metastasis over time in an appropriate animal 
model. The overall anatomy of the murine lymphatic system has not been 
unequivocally determined, even though murine models have been used widely for 
immunology and cancer biology studies. The lack of data arises mainly because it is 
difficult to distinguish lymph nodes (LNs) from their surrounding adipose and 
connective tissue; this is due partly to their small size, and partly because of the 
difficulty in visualizing the lymphatic vessels (LVs) that transport 
clear-to-white-colored lymph fluid.  
It has been reported previously that the lymphatic system in mice consists of 
LVs and 22 types of LN, and the positional relationships of these LNs was revealed 
[178]. This study was carried out using MXH10/Mo/lpr inbred mice that exhibit 
systemic lymphadenopathy, with some peripheral LNs being as large as 10 mm in 
diameter, but show the advantage of not developing the severe glomerulonephritis and 
vasculitis seen in other murine models of lymphadenopathy. The basic structures of 
the LNs, including the medulla, paracortex and cortex, and the lymphatic channels are 
well maintained in MXH10/Mo/lpr mice. Furthermore, the anatomical results are 
essentially consistent with those obtained using BALB/cAnNCrl mice [177]. In the 
present study, the communication routes between the lymphatic and venous systems 
in the axillary and subiliac regions of MXH10/Mo/lpr mice were clarified using 
anatomical and imaging methods. As pointed out previously [177], the way the 
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murine LN nomenclature has been defined is unclear, resulting in misunderstanding 
among researchers. In the present study, the murine LN nomenclature defined by Van 
den Broeck et al. [177] and Shao et al. [178] has been used. The vein that 
communicates with the subclavian vein and the inferior vena cava, and runs adjacent 
to the SiLN and PALN, was termed the TV. 
 
3.3. Materials and Methods 
 
The Institutional Animal Care and Use Committee of Tohoku University (Animal 
Experiments and Related Activities in Academic Research and Technology, 2006) 
approved all in vivo protocols. All anatomical dissections were performed with the 
animal under general anesthesia, and great efforts were taken to minimize animal 
suffering. 
 
3.3.1. Mice 
 
MXH10/Mo/lpr mice are a substrain of the recombinant inbred mouse strain, 
MXH/lpr [178], and were produced using two different parental inbred strains as 
progenitors, MRL/MpJ-lpr/lpr (MRL/lpr) and C3H/HeJ-lpr/lpr, followed by an F1 
intercross and more than 20 generations of strict brother-sister matings. 
MXH10/Mo/lpr mice are unique in that most of their peripheral LNs are up to 10 mm 
in size at 2.5–3 months of age. MXH10/Mo/lpr mice do not develop severe 
glomerulonephritis and vasculitis, in contrast to MRL/lpr mice [169], and thus their 
life span is longer. The phenotype of the lpr (lymphoproliferation) gene is 
characterized by the accumulation of a large number of polyclonal CD4
-
CD8
- 
T cells 
in the LNs and spleen [192]. The lpr gene is recognized as a ‘promoting factor’ for 
collagen disease in MRL mice due to Fas-mediated apoptotic insufficiency; the 
causative genes of collagen disease are considered to be the ‘background’ genes of 
MRL/lpr mice [193]. 
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3.3.2. Identification of the lymphatic and venous systems 
 
Mice were placed under deep general anesthesia with 2.5% isoflurane in oxygen 
(Abbott Japan Co., Ltd., Tokyo, Japan) using an inhalation gas anesthesia system 
designed for small laboratory animals. The LNs and lymphatic and venous vessels 
were surgically exposed and carefully characterized. India ink (20 L) was injected 
into the LNs, using a syringe with a 30G needle, to confirm the lymphatic routes. 
Lymphatic and venous routes were visualized with the aid of a stereomicroscope 
(SZX10, Olympus, Tokyo, Japan), and digital images were recorded (Camedia 
C-5060 Wide Zoom, Olympus). 
 
3.3.3. Production of NDB-liposomes 
 
1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC) (MC8080; NOF Co.), 
1,2-distearoyl-sn-glycerol-3-phosphatidylethanolamine-methoxy-polyethyleneglycol 
(DSPE-PEG[2000-OMe]) (DSPE-020CN, NOF Co.), and 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4
-yl) (NBD-DPPE) (FE6060, NOF Co.) (92:6:2 mol/mol) were dissolved in a sufficient 
quantity of chloroform, and the organic solvent then completely removed during flask 
rotation (60 hPa, at 65C for 2 h). The resulting thin film of liposomes was dissolved 
in phosphate-buffered saline to form multi-lamellar vesicles. After two freeze-thaw 
cycles to form large unilamellar vesicles, the diameter of the fluorescent liposomes 
was adjusted to approximately 600 nm using extruding equipment (Northern Lipids) 
and a filter (pore size, 600 nm). The size and zeta potentials of the NDB-liposomes 
were 642 nm and -1.5 mV, respectively, measured using a particle size and zeta 
potential analyzer (ELSZ-2; Otsuka Electronics, Osaka, Japan).  
 
3.3.4. Visualization of flow in veins 
 
A total of 5 mice were used for these experiments. Each animal was placed under 
deep general anesthesia, an arc-shaped incision was made in the abdominal skin of the 
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mouse from the subiliac to the proper axillary region, and 100 L of 0.01 M 
NBD-liposomes was then injected into the tail vein at a rate of 100 L/min for 60 s. 
Fluid flow in the veins was visualized using a fluorescence stereomicroscope 
(M165-FC; fluorescent filter: GFP2; excitation: 460–500 nm; emission: > 510 nm; 
Leica, Bensheim, Germany) that was connected to a high-speed camera (Cool SNAP 
HQ2; Photometrics, Tokyo, Japan) operating at 10 frames/s. 
 
3.4. Results 
 
3.4.1. Communication between lymphatic and venous systems in the axillary 
and subiliac regions 
 
Figure 3.1 shows the routes of communication between the lymphatic and venous 
systems in the axillary and subiliac regions of the MXH10/Mo/lpr mouse. The 
efferent LVs of the SiLN are connected to the PALN, and the efferent LVs of the 
PALN are connected to the subclavian vein. The TV, which connects the subclavian 
vein and the inferior vena cava, runs adjacent to the SiLN and PALN, and receives 
venous blood draining from these LNs through small branches.  
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Figure 3.1. Communication between the lymphatic and venous systems in the axillary 
and subiliac regions in MHX10/Mo-lpr/lpr mice. The efferent lymphatic vessels of the 
subiliac lymph node (SiLN) connect to the proper axillary lymph node (PALN), and the 
efferent lymphatic vessels of the PALN connect to the subclavian vein. The thoracoepigastric 
vein connects to the subclavian vein and the inferior vena cava via the PALN and SiLN. LN: 
lymph node; Orange: lymphatic; Blue: vein. Figure 3.1 is used with permission. 
 
Figure 3.2 shows magnified images of the right SiLN (Figure 3.2A) and left SiLN 
(Figure 3.2B). When India ink was injected into the SiLN, it ran towards the PALN in 
the efferent LVs of the SiLN. Two efferent LVs that run to the PALN can be seen in 
Figures 3.2A and 3.2B. The TV runs adjacent to the SiLN, receives venous blood that 
drains from the SiLN, and then connects to the inferior vena cava.  
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Figure 3.2. Lymphatic and venous system connections in the left and right subiliac 
lymph nodes (SiLNs). India ink was injected into each SiLN, and drained from the SiLN into 
the efferent lymphatic vessels (LVs) to reach the proper axillary lymph node (PALN). (A) Right 
SiLN region. The right thoracoepigastric vein (TV) is connected to the inferior vena cava. The 
other end of the TV connects to the right subclavian vein via the right PALN. The findings are 
representative of 4 independent experiments. (B) Left SiLN region. The left TV is connected to 
the inferior vena cava. The other end of the TV connects to the left subclavian vein via the left 
PALN. The findings are representative of 3 independent experiments. Figure 3.2 is used with 
permission. 
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Figure 3.3 shows the communication between the efferent LV of the PALN and 
the subclavian vein, in the right PALN (Figure 3.3A) and left PALN (Figure 3.3B) 
regions. These images were obtained by injecting India ink into the PALN, and 
monitoring its progression to the subclavian vein via the efferent LV of the PALN. 
Figure 3.3C shows the venous system connected to the left PALN. The left TV that 
runs adjacent to the left PALN and receives venous blood draining from the PALN 
connects to the left subclavian vein. The efferent LVs that extend from the left SiLN 
make connections with the left PALN. The efferent LV (indicated by the white dotted 
arrow) connects to the left subclavian vein. 
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Figure 3.3. Lymphatic and venous systems near the proper axillary lymph node (PALN). 
(A) Right PALN region. India ink that was injected into the right PALN drained into the 
efferent lymphatic vessel (LV) towards the right subclavian vein. The findings are 
representative of 5 independent experiments. (B) Left PALN region. India ink that was injected 
into the left PALN drained into the efferent LV towards the left subclavian vein. The findings 
are representative of 6 independent experiments. (C) Venous system via the left PALN. The left 
thoracoepigastric vein (TV) that runs via the left PALN connects to the left subclavian vein. 
The efferent LVs that extend from the left SiLN connect to the left PALN as afferent LVs. The 
efferent LV, as indicated by a white dotted arrow, connects to the left subclavian vein. LN, 
lymph node. Figure 3.3 is used with permission. 
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3.4.2. Direction of blood flow in the TV 
 
The TV, which connects the subclavian vein and the inferior vena cava, runs 
adjacent to the SiLN and PALN and receives venous blood draining from these LNs, 
routed through small branches. Next, the direction of blood flow in the TV was 
investigated after injection of fluorescent solution into the tail vein of the mouse 
(Figure 3.4). Figure 3.4B shows a magnified view of the square region labeled ‘X’ 
between the PALN and SiLN, and Figure 3.4E shows a magnified view of the square 
region labeled ‘Y’ over the SiLN. It should be noted that Figure 3.4A is the same as 
Figure 3.1, and does not correspond exactly with the in vivo images shown in Figure 
3.4B and Figure 3.4E. Figure 3.4C shows a frame obtained from Media 1, which 
illustrates the square region ‘X’ indicated in Figure 3.4B. Figure 3.4D shows the 
directions of flow in the vein network connected to the TV in this region; two veins 
are connected to the TV at points ‘b’ and ‘c’, respectively. Flow in the TV occurred in 
two directions: one was oriented towards the subclavian vein at point ‘b’, the other 
towards the SiLN at point ‘c’. The flow stagnated or moved back and forth in sections 
b–c (see Media 1). The bidirectional flow always occurred in the central region 
between the SiLN and PALN where other veins connected to the TV. Figure 3.4F 
shows a frame obtained from Media 2, showing the square region ‘Y’ indicated in 
Figure 3.4E. Figure 3.4G shows the directions of flow in the venous network that 
connected to the TV over the SiLN. Here, the direction of flow in the TV was always 
oriented towards the inferior vena cava (see Media 2). 
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Figure 3.4. Direction of blood flow in the thoracoepigastric vein (TV). (A) Venous 
system in the axillary and subiliac regions (the illustration represents part of that shown in 
Figure 3.1). The direction of flow in the TV was investigated in two regions, labeled X and Y. 
(B) The region ‘X’ between the subiliac lymph node (SiLN) and proper axillary lymph node 
(PALN). (C) A frame obtained from Media 1, showing the square region ‘X’ indicated in 
Figure 3.4B. (D) Directions of flow in the venous network that connected with the TV. Two 
veins connect to the TV at points ‘b’ and ‘c’, respectively. Flow in the TV occurred in two 
directions, one oriented towards the subclavian vein at point ‘b’, the other towards the SiLN 
at point ‘c’. Flow stagnated or moved back and forth in section ‘b–c’ (see Media 1). (E) The 
region ‘Y’ over the SiLN. (F) A frame obtained from Media 2, showing the square region ‘Y’ 
indicated in Figure 3.4E. G. Directions of flow in the venous network that connected with the 
TV in the region of the SiLN. The direction of flow in the TV was oriented towards the inferior 
vena cava (see Media 2). Figure 3.4 is used with permission. 
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3.5. Discussion  
 
The LVs that run from the SiLN towards the PALN are superficial and relatively 
long compared to other LVs. Thus, these LVs have been used in studies of lymphatic 
and tumor cell flows and drug delivery [188, 194-196]. However, the lymphatic flow 
in the efferent LV from the PALN has not been fully investigated. In the present study, 
it was found that the efferent LV from the PALN connected directly to the subclavian 
vein. There are two LNs in the axillary area: the PALN and the accessory axillary LN 
(AALN) [177, 178]. There are no lymphatic routes draining from the PALN to the 
AALN, although draining vessels from the AALN to the PALN have been detected 
[194]．Therefore, there are two lymphatic routes to the subclavian vein in the axillary 
area:  
(i) AALN  PALN  subclavian vein, 
(ii) SiLN  PALN  subclavian vein. 
In most cases, the efferent LV of the SiLN routed towards the PALN has at least 
one bifurcation, i.e., a single LV is relatively uncommon [194]. 
The TV, which connects the subclavian vein and the inferior vena cava, runs 
adjacent to the SiLN and PALN, and receives venous blood that drains from these 
LNs, routed through small branches. The direction of blood flow in the TV occurred 
in two directions in the region intermediate between the PALN and SiLN; one to the 
subclavian vein, the other to the inferior vena cava. The region where bidirectional 
flow occurred was located near the center, between the SiLN and PALN. 
According to the results, there are two routes from the TV to the right atrium of 
the heart:  
(i) TV  (SiLN)  inferior vena cava  right atrium, 
(ii) TV  (PALN)  subclavian vein  superior vena cava  right atrium. 
My laboratory has reported models of LN metastasis suitable for the study of 
diagnostic and treatment methods in both MXH10/Mo/lpr [178, 194, 197] and 
MRL/MpJ-lpr/lpr [166, 198] mice. In these models, tumor cells were injected into the 
SiLN to induce metastasis in the PALN through the lymphatic system. In this 
experimental system, metastasis was observed to occur in the liver and lung as well as 
in the PALN [166]. It is likely that tumor cells disseminated to these organs through 
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the TV after they were injected into the SiLN. Indeed, Evans blue solution injected 
into the SiLN has been visualized to flow into the TV [194]. 
The role that veins located adjacent to the LNs play in tumor cell metastasis has 
not been elucidated to date. From these results, it has been proposed that when tumor 
cells metastasize from the primary tumor to the regional LNs, there is extracapsular 
spread into the veins located around the LNs; although tumor cells may reach the 
secondary LNs through efferent LVs, it is the veins that are primarily responsible for 
the dissemination of these tumor cells throughout the cardiovascular system.  
In the clinic, there are a few cases where tumor cells disseminate to the sentinel 
LNs and secondary LNs in long strings. When the tumor cells spread extracapsularly 
into the surface veins, the metastatic form is shifted from LN metastasis towards 
hematogenous metastasis. Thus, the final form of LN metastasis should be recognized 
as “LN-mediated hematogenous metastasis.”  
A limitationsof the present investigation is the blood vessel nomenclature, e.g., the 
TV nomenclature should be properly addressed. Furthermore, it remains unclear how 
well dyes and liposomes simulate cancer cell metastasis. In addition, the function of 
the communication between the blood vascular system and lymphatics at other LN 
sites remains a mystery and requires further investigation. 
In conclusion, the communication between the lymphatic and venous systems in 
the axillary and subiliac regions of the mouse has been clarified. The efferent LVs of 
the PALN communicated with the subclavian vein. The TV, which connects the 
subclavian vein and the inferior vena cava, runs adjacent to the SiLN and PALN, and 
receives venous blood that drains from these LNs, routed through small branches. The 
flow in the TV occurs in two directions in the region intermediate between the PALN 
and SiLN: one is oriented towards the subclavian vein, the other towards the SiLN. 
The flow in the TV between the SiLN and the inferior vena cava is oriented towards 
the inferior vena cava. It is anticipated that these results will be a starting point for 
more sophisticated in vivo models to aid the development of diagnostic and treatment 
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methods for LN metastasis, and investigation of the fundamental mechanisms 
involved in metastasis.   
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CHAPTER 4 
 
 
Activation of latent metastases in the lung after 
resection of a metastatic lymph node in a mouse 
model of lymph node metastasis 
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4.1. Summary  
 
Iatrogenic induction of regional and distant cancer metastases is a risk associated 
with clinical resection of tumor-positive SLNs. However, there have been no studies 
of this risk in a mouse model of cancer metastasis. Here, it is reported that resection of 
a tumor-bearing SiLN enhanced metastasis to the lung in a mouse model of LN 
metastasis. Bioluminescence imaging revealed that metastatic tumor cells in the 
secondary LN continued to grow after resection of the SiLN, and that the probability 
of metastasis to the lungs was increased when the interval between SiLN inoculation 
and resection was reduced. Furthermore, histological analysis demonstrated that latent 
tumor cells in the lung were stimulated to grow after resection of the SiLN. 
Fluorescence imaging indicated that the route of tumor cell dissemination from the 
SiLN to the lungs was the venous system located around the SiLN. It is speculated 
that this mouse model will be useful for studying the mechanisms of tumor cell 
latency, with a view to improving the detection and treatment of latent metastases. 
 
4.2. Introduction 
Cancer and its associated pathological processes can be taken as a unique 
biological phenomenon involving the invasion of surrounding tissues and metastasis 
to regional and remote areas. 
LN metastasis is an important prognostic factor for many malignant tumors, 
including breast, head and neck cancers, and plays an important role in the 
development of distant metastases to vital organs [151].  
The treatment of LN metastasis with LN resection is limited to those patients who 
can tolerate surgery and where the risk of metastatic foci invading other major organs 
is minimal [194]. Although the area of dissection is determined by clinic-pathological 
guidelines, dissection alone does not control local recurrence in progressive cases and 
thus is used together with adjuvant therapy. Although dissection of the primary tumor 
is beneficial, it may disturb metastatic homeostasis [199], resulting in the activation 
and rapid growth of latent tumors in distant metastases; this has been suggested to 
occur for several cancer types including breast [200], lung [201] and head and neck 
[202] cancers. Recurrence after dissection is a common phenomenon, but the 
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underlying mechanisms are not fully understood. Removal of LNs that have an 
immunological anti-tumor immune role [142] may facilitate the rapid growth of 
distant latent metastases. However, there are no reports on the relationship between 
resection of LNs and the subsequent rapid growth of latent micrometastases, for 
reasons including the microscopic size of tumors, clinical accessibility and the lack of 
an experimental model.   
 Animal models of LN metastasis have been developed using the 
MXH10/Mo/lpr strain of mouse [178]. These models have been used to map the 
lymphatic system [178], demonstrate the plausibility of administering local therapy to 
a metastatic LN [203], and show that a lymphatic drug delivery system can be used to 
deliver agents to LNs outside the dissection area [194].  
 In the present study, MXH10/Mo/lpr mice were used as an experimental model 
of metastasis, and the results showed that dissection of a SiLN inoculated with tumor 
cells resulted in the rapid growth of latent lung tumors. For previously discussed 
reasons (vide supra), the nomenclature used was ‘SiLN’ instead of ‘inguinal LN’ [177, 
178]. 
 
4.3. Materials and Methods 
 
All in vivo studies were carried out in accordance with the recommendations of 
the Guide for the Proper Conduct of Animal Experiments and Related Activities in 
Academic Research and Technology. The protocol was approved by the Institutional 
Animal Care and Use Committee of Tohoku University.  
 
4.3.1. Mice 
 
MXH10/Mo/lpr mice (16–18 weeks of age) were bred under pathogen-free 
conditions in the Animal Research Institute, Tohoku University [178]. MXH10/Mo/lpr 
mice are unique; their most peripheral LNs grow to 10 mm in size at 2.5 to 3 months 
of age and the mice do not develop autoimmune diseases.  
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4.3.2. Cell culture 
 
Malignant fibrous histiocytoma-like KM-Luc/GFP cells stably expressing a fusion 
of the luciferase (Luc) and enhanced-green fluorescent protein (EGFP) genes, and 
C3H/He mouse mammary carcinoma cells (FM3A-Luc) stably expressing the Luc 
gene, were used [166, 178]. KM-Luc/GFP cells were prepared by transfection of 
MRL/MpTn-gld/gld malignant fibrous histiocytoma-like (MRL/N-1) cells using 
pEGFPLuc (BD Biosciences, Franklin Lakes, NJ, USA) and Lipofectin Transfection 
Reagent (Invitrogen, Carlsbad, CA, USA). MRL/N-1 cells were established from the 
spleen of an MRL/gld mouse. The cells have a histocompatibility of H-2
k
, which is the 
same as that of MXH10/Mo/lpr mice. The relative growth rates of KM-Luc/GFP and 
FM3A-Luc cells were 3.8/day and 1.1/day, respectively. 
 
4.3.3. Visualization of flow from the SiLN into the efferent LVs and 
thoracoepigastric vein 
 
Two different dyes were used: India ink and 0.5 mM 5(6)-carboxyfluorescein 
(MW: 376; excitation: 492 nm; emission: 517 nm; Sigma-Aldrich Japan, Tokyo, 
Japan). The former dye was used to visualize the communications between the 
lymphatic and venous systems via the SiLN, while the latter was used to visualize 
dynamically the flow from the SiLN to the lymphatic and venous systems. A 1-mL 
syringe connected to a 27-gauge standard double-wing needle (Terumo Co., Tokyo, 
Japan) was filled with the appropriate solution. To gain access to the LNs, a skin 
incision was made with the mouse under general anesthesia. The solution (60 L) was 
injected near the center of the SiLN either manually (India ink) or by a driven syringe 
pump at a rate of 100 L/min (fluorescence solution). Images were obtained 
immediately after the injections using a stereomicroscope (SZX10, Olympus, Tokyo, 
Japan) for India ink or a fluorescence stereomicroscope (M165-FC; fluorescent filter: 
GFP2; excitation: 460–500 nm; emission: > 510 nm; Leica Microsystems GmbH, 
Bensheim, Germany) connected to a high-speed camera (Cool SNAP HQ2; 
Photometrics, Tokyo, Japan) for fluorescence solution [194].  
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4.3.4. Induction of metastasis to the PALN by injection of tumor cells into the 
SiLN 
 
KM-Luc/GFP and FM3A-Luc cells passaged 3 times were used. KM-Luc/GFP 
(1.0 × 10
6
 cells/mL) or FM3A-Luc (1.35 × 10
7
 cells/mL) cells were suspended in a 
mixture of 20 µL PBS and 40 µL of 400 mg/mL Matrigel (Collaborative Biomedical 
Products, Bedford, Canada). The SiLN was exposed by incision of the overlying skin, 
and the LVs connecting the SiLN to the PALN were clamped (DDP-09-151 clamp; 
Daddy D Pro, Sialkot, Pakistan). Prepared cells were injected into the cortical part of 
the SiLN using a 27G injection needle. The needle was maintained in the same 
position for 5 min to solidify the Matrigel, after which the needle was removed. Then, 
the exposed SiLN was irrigated with 20 mL of saline and excess fluid was aspirated 
(M-20 aspirator; Tokyo M.I. Company, Inc., Tokyo, Japan). Subsequently, the clamp 
was removed, and the wound was sutured with 5-0 polyamide sutures.  
 
4.3.5. Resection of the SiLN  
 
Mice were anesthetized using an inhaled mixture of 2% isoflurane and oxygen. 
After depilation and skin disinfection, a minimally invasive approach was used for 
skin incision and exposure and extirpation of the SiLN (Figure 4.1A). A bipolar 
coagulator (Erbotom VI050C; ERBE Elektromedizin GmbH, Germany) and surgical 
microscope (Leica M80; Leica Microsystems GmbH, Germany) were used to 
facilitate the SiLN resection process. After excision of the SiLN, the surgical area was 
washed thoroughly with 20 mL of saline (37C) to remove any tumor cells that had 
leaked from the SiLN. The skin wound was closed with 5-0 polyamide-interrupted 
sutures. The entire resection procedure was accomplished in 10–15 min. 
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4.3.6. Assessment of tumor and metastasis development through 
measurement of luciferase activity 
 
Tumor development in the SiLN and metastasis to the PALN and lungs were 
detected using an in vivo bioluminescence imaging system (IVIS; Xenogen, USA) 
[198]. This procedure was carried out separately at 6 h, 3 days, 6 days and 9 days 
post-inoculation of KM-Luc/GFP cells into the SiLN, and at 6 h, 3 days, 7 days, 14 
days, 21 days and 28 days post-inoculation of FM3A-Luc cells into the SiLN. For 
KM-Luc/GFP cells, the mice were divided into 5 experimental groups: G-C (control; 
n = 7); G-S (sham; n = 9); G-H6 (SiLN dissected 6 h post-inoculation; n = 8); G-D3 
(SiLN dissected 3 days post-inoculation; n = 4); and G-D6 (SiLN dissected 6 days 
post-inoculation; n = 5). The luciferase activities of the dissected LNs and lungs were 
measured ex vivo by IVIS on day 9. For FM3A-Luc cells, mice were divided into 3 
groups: G-C (control; n = 5); G-H6 (SiLN dissected 6 h post-inoculation; n = 3); and 
G-D21 (SiLN dissected 21 days post-inoculation; n = 3). The luciferase activities of 
dissected LNs and lungs were measured ex vivo by IVIS on day 28 (Figure 4.1. B).  
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Figure 4.1. MXH10/Mo-lpr/lpr mice and experimental schedule. 
(A) MXH10/Mo-lpr/lpr mouse. SiLN: subiliac lymph node, the tumor inoculation site;  
PALN: proper axillary lymph node, the secondary lymph node relative to the upstream SiLN; 
accessory axillary LN: may be distinguished by its constant anatomical position. (B) 
Experimental schedule. a. KM-Luc/GFP cells. The right-sided SiLNs of all mice were 
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inoculated with KM-Luc/GFP cells (60 µL of 3.3×10
5
 cells/mL) on day 0. G-C (control) 
group (n = 7): the SiLN was not removed; G-H6 group (n = 8): the right-sided SiLN of each 
mouse was removed 6 h after inoculation; G-S6h (n = 3): the right-sided SiLN of each mouse 
was sham removed 6 h after inoculation; G-D3 group (n = 4): the right-sided SiLN of each 
mouse was removed 3 days after inoculation; G-S3ds (n = 3): the right-sided SiLN of each 
mouse was sham removed 3 days after inoculation; G-D6 group (n = 5): the right-sided SiLN 
of each mouse was removed 6 days after inoculation; G-S6ds (n = 3): the right-sided SiLN of 
each mouse was sham removed 6 days after inoculation;. Tumor outgrowth and metastasis 
were monitored consecutively by in vivo bioluminescence imaging. All harvested lymph nodes 
and lungs were stored for immunohistochemical (IHC) analysis after ex vivo bioluminescence 
imaging on day 9. b. FM3A-Luc cells. The right-sided SiLNs of all mice were inoculated with 
FM3A-Luc cells (60 µL of 4.5×10
6
 cells/mL) on day 0. G-C (control) group (n = 5): the SiLN 
was not removed; G-H6 group (n = 3): the right-sided SiLN of each mouse was removed 6 h 
after inoculation; G-D21 group (n = 3): the right-sided SiLN of each mouse was removed 21 
days after inoculation. Tumor outgrowth and metastasis were monitored consecutively by in 
vivo bioluminescence. All harvested LNs and lungs were stored for IHC analysis after ex vivo 
bioluminescence imaging on day 28. 
 
4.3.7. Histological analysis 
 
Samples of KM-Luc/GFP cells and FM3A-Luc cells were harvested on day 9 and 
day 28, respectively. All samples were fixed in 10% formaldehyde in PBS for 4 days 
at 4°C, dehydrated, and then embedded in paraffin. Specimens were cut into 2–4 μm 
serial sections and stained with HE or elastic-Masson (EM), or immunostained for 
detection of LYVE-1-positive and CD31-positive cells [198].  
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4.3.8. Statistical analysis 
 
Data are expressed as the mean ± SD or the mean ± standard error of the mean 
(SEM), unless otherwise indicated. Statistical comparisons were made using the 
Mann-Whitney U-test. Values of P < 0.05 were considered to be statistically 
significant. 
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4.4. Results 
 
4.4.1. Ex vivo detection of metastases in the lungs using IVIS 
 
The aim was to investigate whether the activation of latent metastases in the lungs 
was induced after resection of the SiLN that had been inoculated with tumor cells. 
The potential route from the SiLN to the lung was also investigated. Figure 4.2 shows 
the communication between the lymphatic and venous systems via the SiLN. Two 
efferent LVs and one TV in the SiLN region can be seen in Figure 4.2A. Fluorescence 
solution injected into the SiLN entered the TV (Figure 4.2Ba), and then flowed into 
the efferent LV (Figure 4.2Bd).  
The present study regarded the SiLN as a SLN, and was designed to determine 
whether resection of the SiLN influenced the growth of metastatic tumors in the lungs 
and PALN. Tumor cells were injected into the SiLN and bioluminescence imaging of 
the whole animal undertaken at various times after resection of the SiLN (Figure 4.3)  
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Figure 4.2. Communication between the efferent lymphatic vessel (LV) and the 
thoracoepigastric vein (TV) via the subiliac lymph node (SiLN). (A) Communication 
between the efferent LVs and the TV via the SiLN. India ink that was injected into the SiLN 
flowed into the efferent LVs and the TV. (B) Sequential frames from Media 1. Fluorescence 
solution flowed into the efferent LV of the SiLN and the TV. The solution (60 L) was injected 
near the center of the SiLN at a velocity of 50 L/min using a driven syringe pump. (a) 17 s, 
(b) 19 s, (c) 20 s, (d) 27 s, (e) 31 s, (f) 38 s after the start of recording. Fluorescence solution 
that was injected into the SiLN flowed into the TV located adjacent to the SiLN in (a), and 
flowed into the efferent LV in (d). The solution continued to flow from the SiLN into the 
efferent LVs and TV even in (f). Figure 4.2 is used with permission. 
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Figure 4.3A shows the results of bioluminescence imaging of mice in which the 
SiLN had been inoculated with KM-Luc/GFP cells, with subsequent resection of the 
SiLN either 6 h (G-H6; n = 8), 3 days (G-D3; n = 4) or 6 days (G-D6; n = 5) after 
inoculation. The three sham groups, named G-S6h (n = 3), G-S3ds (n = 3) and G-S6ds 
(n = 3), represent mice in which the SiLN was not excised even though the procedures 
of resection were simulated.The control group represents mice in which the SiLN was 
not excised (G-C; n = 7). Metastasis to the PALN was induced in all groups and was 
evident on day 6 in the G-C, G-H6 and G-D6 groups, and on day 9 in the G-D3 group. 
Metastasis to the lungs was detected on day 9 in the G-H6 and G-D3 groups.  
Figure 4.3B shows the normalized luciferase activity of the PALN for each group. 
The luciferase activity of the PALN increased up to day 6 and then stabilized in group 
G-C (no SiLN resection), whereas it increased continuously up to day 9 in mice with 
resected SiLNs. In group G-H6, the luciferase activity of the PALN increased over 
time and exceeded that in group G-C on day 9 (P < 0.05; Figure 4.3B). In groups 
G-D3 and G-D6, the luciferase activity of the PALN increased monotonically over 
time; on day 9, the value in the group G-D6 was significantly lower than that in the 
group G-H6 (P < 0.05; Figure 4.3B).  
Figure 4.3C shows the bioluminescence imaging results from mice in which the 
SiLN was inoculated with FM3A-Luc cells, with SiLN resection carried out either 6 h 
(G-H6; n = 3) or 21 days (G-D21; n = 3) after inoculation; the SiLN was not removed 
in the control group (G-C; n = 5). Metastasis to the PALN in these animals was 
delayed compared to mice inoculated with KM-Luc/GFP cells, and was detected on 
day 21 for groups G-C and G-D21, and on day 28 for group G-H6. This is likely due 
to FM3A-Luc cells having a slower growth rate than KM-Luc/GFP cells. The 
normalized luciferase activity of the PALN increased progressively over time in mice 
with SiLN resection (Figure 4.3D), and was higher in group G-H6 compared to group 
G-C on day 28 (P < 0.05; Figure 4.3D).  
Metastasis to the lungs was detected in mice in which KM-Luc/GFP cells had 
been inoculated into the SiLN (Figure 4.3A). Although not observed by IVIS, it is 
possible that lung metastasis had also occurred in mice inoculated with FM3A-Luc 
cells. Therefore, the lung was investigated using the IVIS ex vivo, on day 9 for 
KM-Luc/GFP cells and day 28 for FM3A-Luc cells (Figure 4.4). In mice in which 
KM-Luc/GFP cells had been inoculated into the SiLN (Figure 4.4A), many small 
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metastatic foci were detected in the lungs of groups with early resection of the SiLN 
(G-H6, G-D3). The luciferase activity for groups G-H6 and G-D3 was significantly 
higher than that for group G-C (P < 0.05; Figure 4.4B). The probability of metastasis 
to the lung was: G-H6 (62.5%) > G-D3 (50.0%) > G-D6 (20.0%) > G-C (14.2%) 
(Figure 4.4C). In experiments using FM3A-Luc cell inoculation, small metastatic foci 
were detected in the lungs in group G-H6, and many metastatic foci were detected 
throughout the entire lung in group G-D21 (Figure 4.4D). The luciferase activity was 
significantly higher in groups G-H6 and G-D21 than in group G-C (P < 0.05; Figure 
4.4E). The probability of metastasis to the lungs was: G-D21 (66.6%) > G-H6 
(33.3%) > G-C (20.0%) (Figure 4.4F). 
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Figure 4.3. Luciferase activities in the subiliac lymph node (SiLN) and proper axillary 
lymph node (PALN) after removal of the SiLN. (A), (B) KM-Luc/GFP cells were injected 
into the SiLN (n = 24). The SiLN was resected 6 h (G-H6 group, n = 8; G-S6h group, n = 3), 
3 days (G-D3 group, n = 4; G-S3d group, n = 3) or 6 days (G-D6 group, n = 5; G-S6d group, 
n = 3) after tumor cell implantation. SiLNs that were injected with KM-Luc/GFP cells but not 
removed were used as control samples (G-C group, n = 7). (A) Mice after resection of SiLNs. 
Metastases were detected in the PALN and lungs. Luciferase activity was not detected in the 
region of the SiLN after the SiLN had been resected. (B) Temporal changes in the luciferase  
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activity of the PALN after resection of the SiLN. The luciferase activity of each group was 
normalized to that of the mean value at 6 h. G-H6 versus G-C, P < 0.05 on day 9; G-H6 
versus G-D6, P < 0.05 on day 9; Mann-Whitney U-test. (C), (D) FM3A-Luc cells were 
injected into the SiLN (n = 11). The SiLN was removed 6 h (G-H6 group, n = 3) or 21 days 
(G-D21 group, n = 3) after tumor cell implantation. SiLNs injected with cells but not resected 
were used as control samples (G-C group, n = 5). (C) Mice after resection of SiLNs. 
Metastases were detected in the PALN and lungs. Luciferase activity was not detected in the 
region of the SiLN after it had been resected. (D) Temporal changes in the luciferase activity 
of the PALN after resection of the SiLN. The luciferase activity of each group was normalized 
to the mean value at 6 h. G-D21 versus G-H6, P < 0.05 on day 3; G-D21 versus G-H6, P < 
0.05 on day 28; Mann-Whitney U-test. Mean ± standard deviation values are shown.  
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Figure 4.4. Ex vivo detection of metastases in the lungs using IVIS. (A), (B), (C) 
KM-Luc/GFP cells. The lungs (L) and caudal mediastinal lymph node (CMLN) were removed 
from mice in the G-C (n = 7); G-H6 (n = 8), G-S6h (n = 3); G-D3 (n = 4); G-S3d (n = 3) and 
G-D6 (n = 5), G-S6d, (n = 3) on day 9. (D), (E), (F) FM3A-Luc cells. The lungs and heart 
were removed from mice in the G-C (n = 5), G-H6 (n = 3) and G-D21 (n = 3) groups on day 
28. (A) Representative ex vivo images of lungs and CMLN. Tumor foci were distributed 
discretely throughout the lungs in groups in which the SiLN had been removed (G-H6, G-D3, 
G-D6). More luciferase-active foci were detected in the groups having early removal of the 
SiLN (G-H6, G-D3). (B) Ex vivo luciferase activity in the PALN. Luciferase activity in the  
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lungs was higher in the groups with early resection of the SiLN than in the control group (G-C 
versus G-H6, P < 0.05; G-C versus G-D3, P < 0.05). (C) Probability of detecting luciferase 
activity in the lungs. Probabilities were increased in the groups with early resection of the 
SiLN. (D) Representative ex vivo images of metastases in the lungs. Tumor foci were detected 
throughout the lungs in the G-H6 group. L: lung. (E) Ex vivo luciferase activity in the lungs. 
Luciferase activity in the lungs was higher in the groups with resection of the SiLN than in the 
control group (G-C versus G-H6, P < 0.05; G-C versus G-D21, P < 0.05). (F) Probability of 
detecting luciferase activity in the lungs. The threshold value to judge the metastasis in the 
lung was 1 × 10
5
 (photons/s). Meta+: number of mice showing induction of lung metastasis; n: 
total number of mice. Mean ± SEM values are shown. Figure 4.3 is used with permission. 
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4.4.2. Histological analysis 
 
The lungs were investigated histologically on day 9 for mice that had been 
inoculated with KM-Luc/GFP cells, and day 28 for mice inoculated with FM3A-Luc 
cells (Figure 4.5). In experiments using KM-Luc/GFP cells (Figure 4.5A, B), a 
metastasis with a diameter of 2 mm was detected in group G-H6, with tumor cells 
extravasating from the pulmonary arteries into the pulmonary parenchyma (Figure 
4.5Aa, b). In group G-D3, a metastasis with a diameter of 200 µm was observed 
(Figure 4.5Ae). EM staining (Figure 4.5Af) and immunostaining for CD31 (Figure 
4.5Ag) revealed tumor cells in the form of a tumor embolus and Matrigel in the 
pulmonary artery; in Figure 4.5B, Matrigel is evident between the endothelium and 
internal elastic lamina and there is growth of endothelial and tumor cells in the lumen 
of the pulmonary artery. In group G-D6 (Figure 4.5Ai-l), small metastatic foci were 
observed in the parenchyma; these had presumably invaded the parenchyma from the 
adjacent pulmonary arteries, but the foci were not associated with the growth of 
CD31-positive endovascular vessels. In experiments using FM3A-Luc cells (Figure 
4.5C, D), tumor cells were found to have extravasated from the pulmonary arteries 
into the pulmonary parenchyma, as shown by EM (Figure 4.5Cb) and CD31 (Figure 
4.5Cc) staining. Tumor emboli were observed at the periphery of pulmonary arteries 
(Figure 4.5D), and Matrigel was present in the peripheral vessel. Active 
CD31-positive cells related to the growth of neovascular vessels were not detected.  
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Figure 4.5. Histological analysis. (A), (B) KM-Luc/GFP cells. (C), (D) FM3A-Luc cells. 
Samples were stained with hematoxylin/eosin, elastic-Masson, anti-CD31 (CD31) or 
anti-LYVE-1 (LYVE-1) techniques. (A) On day 9, the lungs were dissected from the mice: 
groups G-H6 (n = 4), G-D3 (n = 4) and G-D6 (n = 4). Large-sized metastatic foci were 
detected in group G-H6. A small amount of Matrigel (M) containing tumor cells was observed 
between the endothelium and internal elastic lamina of the pulmonary artery (Ae, f, g, h). (B) 
Magnified view of panel Ag. Tumor cells developed as a tumor embolus, which occupied the 
arterial lumen. Matrigel located in the subendothelial region with surrounding fibrosis 
indicates an old event. (C) On day 28, the lungs were dissected from the mice: group G-H6 (n 
= 3). Tumor cells (T) have extravasated from the pulmonary arteries into the pulmonary 
parenchyma. (D) Magnified view of an image obtained from group G-H6 (FM3A-Luc cells). 
Matrigel (M) was detected in the peripheral vessel. Figure 4.4 is used with permission. 
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4.5. Discussion  
 
Resection of SiLNs inoculated with tumor cells led to an accelerated growth of 
metastatic tumor cells in the lungs and PALN. Thus, tumor cells injected into the 
SiLN had clearly spread to the lungs via the venous system around the SiLN and the 
TV (Figure 4.2). Although the flow of fluorescence solution in the efferent LV of the 
SiLN in MXH10/Mo/lpr mice has been visualized by our group [194], there are in 
fact two routes: one towards the PALN via the LV, i.e. related to lymphogenous 
metastasis to the PALN, and another towards the venous system via the TV, i.e. 
related to hematogenous metastasis throughout the body. The lungs are the first organs 
that are reached by tumor cells disseminated into the venous system, and the tumor 
cells become trapped in pulmonary capillaries. In the case of KM-Luc/GFP cells, 
tumor cells with Matrigel that had moved into the pulmonary artery were detected 
between the endothelium and internal elastic lamina (Figure 4.5B). There are two 
routes by which the mixture of tumor cells and matrigel inoculated into the SiLN could 
colonize the lung: one is via the TV, the other is via the lymphatics with transfer from 
the PALN to the subclavian vein. We believe the former route is the more likely one by 
which a tumor cell and matrigel mass reaches the lung, while the latter route can result 
in colonization of the PALN and lung metastasis. 
This finding indicates that the tumor cells existed in a latent state and had been 
enveloped with endothelium. These tumor cells subsequently started to grow after 
resection of the SiLN. A similar tendency was observed for FM3A-Luc cells (Figure 
4.3).   
Tumor latency is one stage of tumor development that lacks clinical symptoms 
[204]. Two mechanisms have been implicated in tumor latency; one involves the 
antagonism of the expansion of a population of dividing tumor cells (tumor mass 
latency), and the other involves the arrest of tumor cell growth (tumor cell latency or 
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cellular latency) [205]. It was not possible to determine which mechanism 
corresponded to the latent tumor that was observed to grow in the present study. 
 Tumor latency occurs in primary and secondary tumors during the early stages of 
tumor development, during the micro-metastasis stage, and following surgical 
resection [206]. Recurrence of cancer frequently occurs after treatment or long 
periods of remission. For instance, 20–45% of patients with breast or prostate cancer 
will relapse a few years or even decades later [205], because latent tumor cells that 
remain after removal or treatment of the primary tumor are resistant to chemotherapy. 
 In the present study, tumor cells in the metastasis sites (i.e., PALN or lung) were 
activated in mice in which the SiLN had been resected 6 h, 3 days or 6 days after 
inoculation of KM-Luc/GFP cells, and 6 h or 21 days after inoculation of FM3A-Luc 
cells. This activation of tumor cells is consistent with previous results suggesting that 
tumor latency could occur at an early stage of tumor development [207]. 
The concentration of serum VEGF increases and that of serum endostatin 
decreases after pulmonary/breast surgery [208]. These changes may well accelerate 
the growth of a latent tumor [201]. In the present study, the proliferation of 
CD31-positive endothelial cells, an indicator of active neovascularization, was not 
detected in pulmonary metastatic foci. Thus, it is unlikely that the accelerated growth 
of metastatic foci was triggered by the proliferation of tumor neo-vascular vessels. It 
may be that tumor neo-vascular vessels are not required for tumor growth because of 
the abundant blood flow in the pulmonary parenchyma. Dillekas and colleagues [209] 
have hypothesized that multiple similar-sized metastases, at the time of first 
recurrence, occur due to synchronized growth kinetics. It will be interesting to extend 
the present study by investigating the size distribution of the metastatic foci in the 
lungs. 
The limitation of the present study is that the mechanism of this experimental 
phenomenon needs more thorough investigation with regard to morphology, 
molecular biology and genetics. In addition, it will be necessary to validate the 
experimental findings in a model of spontaneous cancer metastasis and translate this 
research into clinical investigations. 
In future, the “niche” state of distant organs should be investigated at the 
morphological, cellular and molecular levels, both before and after the resection of a 
tumor-bearing LN, to provide direct insight into the mechanisms by which 
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tumor-bearing LN resection induces distant metastasis. In the meantime, evidence 
from clinical studies could be used as an alternative approach to determining whether 
the current clinical protocol for SLNB should be revised in order to prevent or 
minimize the ‘iatrogenic’ activation of distant metastatic foci. 
In conclusion, the experimental mouse model described here allowed observations 
on the activation and development of microscopic metastatic foci, which occurred 
after LN resection, in a reproducible fashion and on a real-time basis. This model may 
prove to be very useful for the elucidation of the mechanisms of tumor latency and for 
the development of methods to either extend the latent state, inhibit tumorigenesis at 
an early stage, or prevent the formation of metastases. 
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CHAPTER 5 
 
 
Conclusions 
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Cancer metastasis is the most fatal characteristic of malignant cancers. Metastatic 
tumor cells spread through the blood and/or LVs in most forms of human cancer. The 
steps in the hematogenous invasion-metastasis cascade are extraordinarily inefficient, 
with a rate of attrition that often exceeds 99% of those cells that initially survive in a 
foreign microenvironment to form micro-metastases. Lymphatics can facilitate cancer 
cell dissemination. Compared with blood vessels, the LV pathway offers many 
advantages for invasion and transport of pre-metastatic cells or embolism, just as it 
does for white blood cells, such as: 1) a discontinuous basement membrane and loose 
cell-cell junctions; 2) orders of magnitude slower flow rate that increases survival by 
minimizing shear stress; and 3) a 1000-fold higher lymph concentration of hyaluronic 
acid, a molecule with potent cell-protecting and pro-survival properties. Despite the 
importance of tumor-associated LVs for cancer progression, little information is 
currently available compared with their blood vessel counterparts, partly because the 
structure of the lymphatic system has still not been fully delineated. Lymphatic 
vessels are found in all vascularized organs and tissues with a few exceptions where 
drainage of interstitial fluid occurs perivascularly or via a venous network. The 
lymphatic system consists of a fluid (lymph), vessels that transport the lymph, and 
organs or structures that contain lymphoid tissue. One of the functions of the 
lymphatic system is to act as a holding reservoir for the ‘incubation’ of white blood 
cells; this function can be usurped under pathological conditions by proliferating 
tumor cells, allowing them to form disseminating tumors. In the clinic, the LN status 
of patients with cancer is critical in the diagnosis, staging, treatment and follow-up. In 
melanoma, SLNB is one method of reliably sampling LNs to which tumor cells have 
metastasized. The SLN(s) is (are) defined as the first node(s) to which drainage and 
metastases from a primary cancer occurs. This concept was originally developed for 
melanoma, and since then has been adapted for application to oral and several other 
malignancies, in particular breast carcinoma. In line with the SLN concept, the 
diagnostic and treatment methods have developed from traditional imaging methods 
to the use of minimally- or non-invasive techniques, although problems exist in the 
translation of theory into practice.  
To change the present situation, preclinical animal models of LN metastasis are 
needed. These will prove indispensable in unveiling tumor cell trafficking patterns, an 
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understanding of which is fundamental for the design of new techniques with which to 
diagnose and treat LN metastasis. 
Presently, two contrasting paradigms are used to explain the formation of distant 
organ metastases: a lymphatic-independent hematogenous model and a 
lymphatic-dependent sequential model. The most crucial issue to resolve is whether 
metastatic cells come to a halt in LNs, or whether they continue to disseminate 
throughout the body by using either LN vascular vessels or efferent LVs to colonize 
distant organs via the blood circulation. So far, details of this process remain a 
mystery. However, there is now little doubt that the lymphatic system is the main 
route used by solid cancers to spread. 
With regard to the role played by the lymphatic system in cancer metastasis, 
several issues remain that need to be resolved in preclinical animal models of 
metastasis. First, the structure of the lymphatic system and the relationship between 
the two vascular systems has not been fully elaborated. Second, the mechanism by 
which tumor cells enter the lymphatics (intra-tumoral or peri-tumoral) has not been 
fully characterized. Third, the degree to which LN metastases directly contribute to 
distant organ metastasis needs to be defined. 
This work in this thesis has described the topography of 22 LNs and 4 peripheral 
drainage lymph routes in MXH10/Mo/lpr mice, which can be used to explore cancer 
metastasis in the peripheral lymphatic system in a preclinical setting. In addition, this 
thesis has clarified the routes of communication between the lymphatic and venous 
systems in the axillary and subiliac regions of the mouse, and demonstrated that the 
LV running from the SiLN to the PALN is capable of draining tumor cells. Moreover, 
this thesis has also revealed that lung metastatic foci could be rapidly activated 
following resection of a tumor-bearing SiLN. It is anticipated that this mouse model 
will be useful for studies of LV imaging, lymphatic trafficking kinetics, and 
mechanisms of tumor-lymphatic interplay during regional and distant metastasis. 
Furthermore, it is anticipated that data acquired with this murine model will translate 
into improved methods for clinic diagnosis and drug delivery. 
Iatrogenic induction of regional and distant cancer metastases is a risk associated 
with clinical resection of tumor-positive SLNs. However, there have been no studies 
of this risk in a mouse model of cancer metastasis. Based on the data described in this 
thesis and a search of the literature, the concept of iatrogenic metastasis has been 
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considered, and a hypothesis proposed that dissection of a tumor-positive SLN 
(SLNB) risks promoting cancer metastasis. It is speculated that in the process of 
SLNB, tumor foci anchored early in regional or distant sites are potentially ‘woken’ 
or unwittingly provided with more ‘seeds’ and/or ‘soil’ from the ‘perturbed’ SLNs. 
When a tumor-positive SLN is removed, the inhibition of angiogenesis in distant 
dormant metastatic foci may be attenuated by the termination of anti-angiogenic ECM 
proteins released from tumor foci in the SLN. As shown in chapter 4, preclinical 
simulations have provided support for this hypothesis. However, the studies needed to 
extrapolate the findings of preclinical investigations to the clinical setting remain in 
development. A well-designed preclinical investigation is warranted to test the 
hypothesis further and evaluate the metastasis outcomes of tumor-positive SLN 
resection. Moreover, prospective cohort studies or randomized controlled clinical 
trials are needed to verify the hypothesis in patients. 
Our laboratory has already carried out a study in a mouse model of lymphatic 
metastasis to investigate the effects of dissection of an upstream positive LN on 
metastasis [178]. To date, only a pilot study has confirmed that exogenic LN tumor 
biopsy can accelerate tumor metastasis in the lung [210]. However, how the 
enhancement of lung metastasis occurs after early tumor-positive LN dissection in this 
animal model remains unknown. 
It is speculated that the mechanisms underlying the interaction of cancer 
metastatic foci and stroma, lymphangiogenesis and LV remodeling that occur during 
cancer metastasis could also be investigated using this model, in which the LN 
topography and lymphatic-vascular communications have been clarified. Such studies 
will shed important light on how the lymphatic system contributes to the spread of 
cancer cells.  
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